Compositions and methods for facilitating interspecies chimerism

WO2024186913A3PCT designated stage expired Publication Date: 2024-11-07BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/018702
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-07
Filing Date
2024-03-06
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current methods for generating interspecies chimeras face challenges in achieving robust chimerism between evolutionarily distant species, such as humans and animals like mice and pigs, due to xenogeneic barriers, including differences in developmental pace and cell adhesion, and existing strategies are not practical for regenerative medicine due to oncogenic modifications.

Method used

Engineered pluripotent cells with a functionally defective retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) signaling pathway, achieved through gene knockouts or inhibitors, are used to facilitate human or non-human cell establishment and proliferation in chimeric cell populations, allowing for the generation of humanized tissues or organs in non-human animals.

Benefits of technology

The approach enhances the feasibility of generating human and non-human tissues and organs in animals, suitable for transplant, by suppressing the RLR signaling pathway, thereby improving interspecies chimerism and reducing oncogenic risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024018702_07112024_PF_FP_ABST
    Figure US2024018702_07112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided here are compositions and method for use in development of interspecies chimera for research and medical purpose. The compositions include engineered stem cells and blastocysts that are defective in the "retinoic acid-inducible gene I (RIG-I)-like receptor" (RLR) signaling pathway.
Need to check novelty before this filing date? Find Prior Art

Description

TITLECOMPOSITIONS AND METHODS FOR FACILITATING INTERSPECIES CHIMERISMCROSS REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 488,889, filed March 7, 2023, and titled “COMPOSITIONS AND METHODS FOR FACILITATING INTERSPECIES CHIMERISM,” which is incorporated by reference herein in its entirety.ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with government support under Grant No. HD103627, awarded by the National Institutes of Health. The government has certain rights in the invention.INCORPORATION OF SEQUENCE LISTING

[0003] The present application contains a Sequence Listing that which has been submitted in .xml format via Patent Center and is hereby incorporated by reference in its entirety. The said WIPO Sequence Listing was created on March 05, 2024, XML copy is named 106546- 789025. xml, and is 39,000 bytes in size.BACKGROUND

[0004] 1 . Field

[0005] The present invention relates to compositions and methods that facilitate interspecies chimerism for production of humanized tissues or organs in non-human animals.

[0006] 2. Discussion of Related Art

[0007] Organ and tissue transplant can save lives, however according to the CDC on any given day in the United States (US), there are around 100,000 people on the active waiting list for organs, but only approximately 14,000 deceased organ donors (data from 2021), with each providing on average 3.5 organs. Living donors provide on average only around 6,000 organs per year. Additionally, in the US, around 3.3 million tissue grafts are distributed each year. About 2.5 million grafts are transplanted. Organ and graft rejection is also a common problem that can result in serious complications and even death.

[0008] The technique of generating interspecies chimeras using human pluripotent stem cells (hPSCs) is a promising in vivo platform to study human development and offers a potential source for growing personalized human tissue and donor organs in animals. Although robust chimerism can be achieved between closely related species, it is far more difficult togenerate chimeras between evolutionarily distant species. The low chimerism of human cells in animals (e.g., mice and pigs) is presumably due to multiple xenogeneic barriers during early development, which include but are not limited to differences in developmental pace, incompatibility in cell adhesion molecules, and interspecies cell competition. Several strategies have been developed to improve human cell chimerism in animal embryos by genetically inhibiting human cell apoptosis. However, these strategies are not practical for future use in regenerative medicine as the modified genes and pathways are mostly oncogenic.

[0009] There is therefore a need in the field for methods to facilitate and improve human or non-human cell establishment and proliferation in chimeric cell populations with non-human animals.SUMMARY OF THE INVENTION

[0010] In some aspects, the current disclosure encompasses an engineered pluripotent cell derived from a non-human animal, wherein the engineered pluripotent cell has a functionally defective “retinoic acid-inducible gene I (RIG-l)-like receptor” (RLR) signaling pathway. In some aspects, the engineered pluripotent cell is functionally defective for one or more of mitochondrial anti-viral signaling protein Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7 or any combination thereof. In some aspects, the engineered pluripotent cell is a gene knock out or knock in for one or more of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7 or any combination thereof. In some aspects, the engineered pluripotent cell is treated with an inhibitor of one or more of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7, to suppress the retinoic acid-inducible gene I (RIG-I)- like receptor” (RLR) signaling pathway. In some aspects, the engineered pluripotent cell may be defective in IRF3 dimerization. In some aspects, the engineered pluripotent cell is an epiblast stem cell. In some aspects, the non-human animal source from which the pluripotent stem cell is derived is a mammal. In some aspects, the mammal is a rodent, a porcine, an ovine, or a bovine animal. In some aspects, the engineered pluripotent cells may comprise additional genetic modifications.

[0011] In some aspects, the current disclosure encompasses a population of cells comprising at least an engineered pluripotent cell as provided herein or a progeny thereof and at least a human or non-human animal stem cell or a progeny thereof, wherein the human or non-human animal stem cell is any one of an induced pluripotent stem cell, embryonic stem cell, or a variant thereof.

[0012] In some aspects, the current disclosure also encompasses a cell culture comprising at least an engineered pluripotent cell as disclosed herein or a progeny thereof and at least a human or non-human animal stem cell or a progeny thereof, wherein the human or non-humananimal stem cell is any one of an induced pluripotent stem cell, embryonic stem cell, or a variant thereof.

[0013] In some aspects, the current disclosure additionally encompasses a chimeric embryo, tissue or organ comprising an engineered pluripotent cell as disclosed herein or a progeny thereof and at least a human or non-human animal stem cell or a progeny thereof.

[0014] In some aspects, the current disclosure also encompasses a method of producing a human or non-human cell population, a tissue, and / or an organ in a non-human animal of a different species, the method comprising: microinjecting a human or non-human animal stem cell in a non-human blastocyst of a different species, thereby generating a chimeric embryo, wherein the non-human blastocyst is functionally defective for one or more of Mavs, Rig-1, Mda5, Ikke, Tbk1, Irf3, lrf7 or any combination thereof. In some aspects of the method disclosed herein, the non-human blastocyst may comprise a gene knock out or knock in for one or more of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7 or any combination thereof. In some aspects, the blastocyst has been previously administered with a composition comprising a RNA guided nuclease and at least one of a Mavs, Ddx58, Irf7 or Ifihl targeting sgRNA at the zygotic stage. In some aspects, the sgRNA comprises a nucleic acid sequence at least about 90% identical to any one of SEQ ID NOS: 1-7. In some aspects, the non-human blastocyst may have been treated with an inhibitor of the “retinoic acid-inducible gene I (RIG-l)-like receptor” (RLR) signaling pathway. In some aspects, the inhibitor specifically inhibits MAVS, RIG-I, MDA5, or Irf7 protein.

[0015] In some aspects, the method disclosed herein further comprises growing the blastocyst ex vivo for at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days or more. In some aspects, the method may further comprise transplanting the chimeric embryo to a surrogate mother.

[0016] In some aspects, the current disclosure encompasses a method for generating a chimeric embryo, the method comprising: administering to a zygote of a non-human embryo, a composition comprising an RNA guided nuclease and a sgRNA targeting one or more of Mavs, Rig-1, Mda5, Ikke, Tbk1, Irf3, Irf7 or any combination thereof, thereby causing the cell to be defective in one or more of Mavs, Rig-1, Mda5, Ikke, Tbk1, lrf3, Irf7 or any combination thereof; culturing the embryo to a blastocyst stage; microinjecting stem cell from a human or a non-human animal from a different species, into the blastocyst to generate a chimeric embryo; transferring the chimeric embryo to a surrogate mother, such that the chimeric embryo comprises non-human cell and human cells, or non-human cells from different species. In some aspects, the sgRNA comprises a nucleic acid sequence at least about 90% identical to any one of SEQ ID NOS: 1-7. In some aspects, the method may further comprisegrowing the chimeric embryo ex vivo for at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days or more before transfer to a surrogate mother. In some aspects, the nonhuman animal is a mammal. In some aspects, the non-human mammal is a rodent, a porcine, a bovine or an ovine. In some aspects, the engineered embryo as disclosed herein may further comprising additional genetic modifications.

[0017] In some aspects, the current disclosure also encompasses use of a human or non- human chimeric tissue and / or an organ produced by any of the methods as disclosed herein for medical purposes. In some aspects, the human or non-human chimeric tissue and / or an organ produced by the disclosed methods may be used for one or more of toxicology, physiology or developmental biological studies. In some aspects, the disclosure also encompasses use of a chimeric organ comprising an engineered pluripotent cell as disclosed herein or progeny thereof and at least a human or non-human animal stem cell or progeny thereof for transplant in a subject of need thereof. In some aspects, the subject is a non-human mammal. In some aspects, the subject is a human.BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. Aspects of the present disclosure are illustrated by way of example in which:

[0019] FIG. 1A provides a schematic of human and mouse PSC co-culture and RNA-seq experimental setup.

[0020] FIG. 1 B are graphs providing statistics of bulk RNA-seq reads in mEpiSCs that could map to mouse genome. Sep, Co-d1 , Co-d2, Co-d3 represent separate culture, co-culture on days 1 , 2, 3, respectively.

[0021] FIG. 1C is a graph providing statistics of bulk RNA-seq reads in mEpiSCs that could map to mouse genome. Sep-T and Co-T represent separate culture in transwell and co-culture in transwell, respectively.

[0022] FIG. 1 D is a graph providing the statistics of bulk RNA-seq reads in H9 hES cells that could map to human genome. Sep, Co-d1 , Co-d2, Co-d3, Sep-T and Co-T represent separate culture, co-culture on days 1 , 2, 3, separate culture in transwell and co-culture in transwell, respectively.

[0023] FIG. 1 E is a Venn diagram showing the numbers of co-URGs in mEpiSCs. Right, KEGG pathway analysis of co-URGs in mEpiSCs. The color of each dot represents log™-transformed P value of each term, while the dot size represents the number of co-URGs in each term. Terms that are not significantly enriched are shown in gray.

[0024] FIG. 1 F provides KEGG pathways enriched on day 1 co-URGs in mEpiSCs. Top 15 (with the lowest P values) KEGG pathways are shown.

[0025] FIG. 1G provides KEGG pathways enriched on day 2 co-URGs in mEpiSCs. Top 15 (with the lowest P values) KEGG pathways are shown.

[0026] FIG. 1 H provides KEGG pathways enriched on day 3 co-URGs in mEpiSCs. Top 15 (with the lowest P values) KEGG pathways are shown.

[0027] FIG. 11 is a heatmap showing fold changes of RLR-pathway-related genes in cocultured versus separately cultured mEpiSCs. Blue and red represent Iog2-transformed fold changes < 0 and > 0, respectively. Asterisks indicate statistically differentially expressed.

[0028] FIG. 1 J provides an RT-qPCR analysis of relative expression levels of RLR-pathway- related genes in co-cultured WT mEpiSCs compared to separately cultured WT mEpiSCs. n = 3, biological replicates. Data are mean ± s.e.m. P values determined by unpaired two-tailed t-test.

[0029] FIG. 1 K is a volcano plot showing significantly upregulated (red) and downregulated (blue) genes in co-cultured versus separately cultured mEpiSCs on day 1.

[0030] FIG. 1 L is a volcano plot showing significantly upregulated (red) and downregulated (blue) genes in co-cultured versus separately cultured mEpiSCs on day 2.

[0031] FIG. 1 M is a volcano plot showing significantly upregulated (red) and downregulated (blue) genes in co-cultured versus separately cultured mEpiSCs on day 3.

[0032] FIG. 2A provides a Native gel electrophoresis experiment detecting IRF3 dimerization in WT mEpiSCs transfected with poly (l:C), co-cultured and separately cultured WT mEpiSCs, co-cultured and separately cultured MavsKO mEpiSCs.

[0033] FIG. 2B is a volcano plot showing no differentially expressed genes in transwell co- cultured versus separately cultured mEpiSCs.

[0034] FIG. 2C provides the KEGG pathway analysis of upregulated genes in mEpiSCs co- cultured with P65KO hiPSCs (versus separate cultures). The color of each dot represents Iog10-transformed P value of each term, while the dot size represents the number of co-URGs in each term. Terms that are not significantly enriched are shown in gray.

[0035] FIG. 2D is a heatmap showing fold changes of RLR-pathway-related genes in mEpiSCs co-cultured with P65KO hiPSCs (versus separate cultures). Blue and red represent Iog2-transformed fold changes < 0 and > 0, respectively. Asterisks indicate statisticallydifferentially expressed.

[0036] FIG. 2E is a Venn diagram showing the numbers of co-URGs in H9 hES cells.

[0037] FIG. 2F provides KEGG pathway analysis of co-URGs in H9 hES cells. The color of each dot represents Iog10-transformed P value of each term, while the dot size represents the number of co-URGs in each term. Terms that are not significantly enriched are shown in gray.

[0038] FIG. 2G is a heatmap showing fold changes of RLR-pathway-related genes in cocultured versus separately cultured H9 hES cells. Blue and red represent Iog2-transformed fold changes < 0 and > 0, respectively.

[0039] FIG. 2H provides KEGG pathways enriched on day 1 co-URGs in H9 hES cells. Top 15 (with the lowest P values) KEGG pathways are shown.

[0040] FIG. 2I provides KEGG pathways enriched on day 2 co-URGs in H9 hES cells. Top 15 (with the lowest P values) KEGG pathways are shown.

[0041] FIG. 2J provides KEGG pathways enriched on day 3 co-URGs in H9 hES cells. Top 15 (with the lowest P values) KEGG pathways are shown.

[0042] FIG. 2K is a volcano plot showing significantly upregulated (red) and downregulated (blue) genes in co-cultured versus separately cultured H9 hES cells on day 1. RLR-pathway- related genes are highlighted.

[0043] FIG. 2L is a volcano plot showing significantly upregulated (red) and downregulated (blue) genes in co-cultured versus separately cultured H9 hES cells on day 2. RLR-pathway- related genes are highlighted.

[0044] FIG. 2M is a volcano plot showing significantly upregulated (red) and downregulated (blue) genes in co-cultured versus separately cultured H9 hES cells on day 3. RLR-pathway- related genes are highlighted.

[0045] FIG. 3A is a schematic of mouse Mavs gene targeting with two sgRNAs and homozygous 1 ,6-kb deletion (233-bp out-of-frame deletion in CDS) in m EpiSC clone C2. Bold, PAM sequence.

[0046] FIG. 3B is a western blot confirming the lack of MAVS protein expression in several independent MavsK° mEpiSC clones. Tubulin was used as a loading control.

[0047] FIG. 3C are representative brightfield and immunofluorescence images showing long-term cultured / WavsKOmEpiSCs maintained stable colony morphology and expressed core (OCT4, red; SOX2, green) pluripotency markers. Blue, DAPL Scale bars, 100 pm.

[0048] FIG. 3D is a RT-qPCR analysis of relative expression levels of RLR-pathway-relatedgenes in co-cultured MavsKOmEpiSCs compared to separately cultured MavsKOmEpiSCs. n = 3, biological replicates. Data are mean ± s.e.m. P values determined by unpaired two-tailed t-test.

[0049] FIG. 3E provides growth curves of H9 hES cells in co-culture with WT mEpiSCs (red), co-culture with MavsKOmEpiSCs (green) and separate culture (blue), n = 6, biological replicates.

[0050] FIG. 3F provides growth curves of WT mEpiSCs in co-culture (red) with H9 hES cells and separate culture (blue), MavsKOmEpiSCs in co-culture (green) with H9 hES cells and separate culture (orange), n = 6, biological replicates.

[0051] FIG. 3G Representative fluorescence images of day-3 co-cultured and separately cultured WT mEpiSCs (red), MavsKOmEpiSCs (red) and H9 hES cells (green). Scale bar, 200 pm..

[0052] FIG. 3H provides growth dynamics of human-mouse 3-day-co-culture assay. Growth curves of H9 hES cells in co-culture with WT mEpiSCs (red), co-culture with MavsK° mEpiSCs (green) and separate culture (blue), n = 4, biological replicates. Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison.

[0053] FIG. 3I provides growth dynamics of human-mouse 3-day-co-culture assay growth curves of WT mEpiSCs in co-culture (red) with H9 hES cells and separate culture (blue), MavsKOmEpiSCs in co-culture (green) with H9 hES cells and separate culture (orange), n = 4, biological replicates. Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison.

[0054] FIG. 3J are representative fluorescence images of day-3 co-cultured and separately cultured WT mEpiSCs (green), MavsK° mEpiSCs (green) and H9 hES cells (red) in MEF- coated micropattern wells. White, DAPL Scale bar, 100 pm.

[0055] FIG. 3K is a dot-plot showing numbers of live H9 hES cells in separate culture (n = 6), co-culture with WT mEpiSCs (n = 5) and co-culture with MavsK° mEpiSCs (n = 5) on day 3 in micropatterned wells, n, biological replicates.

[0056] FIG. 4A is a schematic of mouse Ddx58 gene targeting with two sgRNAs and homozygous 1.5-kb deletion (139-bp out-of-frame deletion in CDS) in Ddx58KOclone. Middle, schematic of mouse Ifihl gene targeting with one sgRNA and homozygous 64-bp out-of-frame deletion in lfih1K° clone (upper). Lower: schematic of mouse Irf7 gene targeting with two sgRNAs and homozygous 655-bp deletion (305-bp out-of-frame deletion in CDS) in IrfT*0clone. Bold, PAM sequence.

[0057] FIG. 4B is a representative brightfield and immunofluorescence images showinglong-term cultured Ddx58KO, lfih1KOand IrfT*0mEpiSCs maintained stable colony morphology and expressed core (OCT4, red; SOX2, green) pluripotency markers. Blue, DAPI. Scale bars, 100 pm. 4C provides growth curves of co-cultured WT, MavsKO, Ddx58KO, lfih1KOand s normalized to corresponding separate cultures, n = 6 (WT), n = 6 ( / WavsKO), n, n = 3 (Jfih1KO) and n = 3 ( / rf^0) independent culture experiments.

[0059] FIG. 4D provides growth curves of co-cultured and separately cultured WT mEpiSCs. n = 6 independent culture experiments. Data are mean ± s.e.m. P values determined by unpaired two-tailed t-test.

[0060] FIG. 4E provides growth curves of co-cultured and separately cultured Ddx58KOmEpiSCs. n = 3 independent culture experiments. Data are mean ± s.e.m. Pvalues determined by unpaired two-tailed t-test.

[0061] FIG. 4F provides growth curves of co-cultured and separately cultured lfih1K° mEpiSCs. n = 3 independent culture experiments. Data are mean ± s.e.m. Pvalues determined by unpaired two-tailed t-test.

[0062] FIG. 4G provides growth curves of co-cultured and separately cultured Irf7^° mEpiSCs. n = 3 independent culture experiments. Data are mean ± s.e.m. Pvalues determined by unpaired two-tailed t-test.

[0063] FIG. 4H provides growth curves of bovine ES cells in co-culture with WT mEpiSCs (red), co-culture with MavsKOmEpiSCs (green) and separate culture (blue), n =3, biological replicates. All data are mean ± s.e.m. Pvalues determined by one-way ANOVA with Dunnett’s multiple comparison.

[0064] FIG. 4I provides growth curves of WT mEpiSCs in co-culture (red) with bovine ES cells and separate culture (blue), MavsKOmEpiSCs in co-culture (green) with bovine ES cells and separate culture (orange), n =3, biological replicates. All data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison.

[0065] FIG. 4J provides growth curves of rhesus ES cells (ORMES23) in co-culture with WT mEpiSCs (red), co-culture with MavsK° mEpiSCs (green) and separate culture (blue).

[0066] FIG. 4K provides growth curves of WT mEpiSCs in co-culture (red) with rhesus ES cells (ORMES23) and separate culture (blue), MavsK° mEpiSCs in co-culture (green) with rhesus ES cells (ORMES23) and separate culture (orange), n =3, biological replicates. All data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison.

[0067] FIG. 4L provides representative fluorescence images of day-4 co-cultured and separately cultured WT mEpiSCs (red), MavsKOmEpiSCs (red) and rhesus ES cells (ORMES23) (green). Scale bar, 200 pm.

[0068] FIG. 4M provides representative fluorescence images of day-4 co-cultured and separately cultured WT mEpiSCs (red), MavsKOmEpiSCs (red) and bovine ES cells (green).Scale bar, 200 pm.

[0069] FIG. 4N provides RT-qPCR analysis of relative expression levels of RLR-pathway- related genes in days 1 , 2 and 3 co-cultured (with bovine ES cells) MavsKOmEpiSCs compared to separately cultured MavsK° mEpiSCs. n = 3, biological replicates. Data are mean ± s.e.m. P values determined by unpaired two-tailed t-test.

[0070] FIG. 5A provides a schematic showing the generation of ex vivo and in vivo humanmouse chimera using / Wavs-deficient mouse blastocysts.

[0071] FIG. 5B provides representative brightfield and fluorescence merged images of WT and / WavsKOmouse embryos cultured for 3 days (d3) and 5 days (d5) after blastocyst injection with hiPSCs. Scale bar, 100 pm.

[0072] FIG. 5C provides line graphs showing the percentages of eGFP+ mouse embryos at indicated time points during ex vivo culture after injecting hiPSCs into WT and MavsKOblastocysts, n = 3 (WT) and n = 3 ( / WavsKO) independent injection experiments. Data are mean ± s.e.m. P values determined by unpaired two-tailed t-test.

[0073] FIG. 5D is a dot plot showing the percentages of eGFP+ E8.5-9.5 mouse embryos derived from injecting hiPSCs into WT and / WavsKO blastocysts. Each blue dot represents one embryo transfer experiment, n = 4 ( / Wavs+ / +), n = 4 ( / Wavs+ / j and n = 7 ( / Wavs_ / , independent experiments.

[0074] FIG. 5E provides representative immunofluorescence images showing contribution of eGFP-labelled hiPSCs in E9.5 mouse embryos. Embryo sections were stained with antibody against eGFP and DAPL Scale bars, 500 pm (whole embryo) and 50 pm (insets) .

[0075] FIG. 5F provides data from genomic PCR analysis of E8.5-9.5 mouse embryos derived from injecting hiPSCs into WT and MavsK° blastocysts. TPA25-Alu denotes a humanspecific primer; PTGER2 was used as a loading control. HFF, HFF-hiPS cells. NTC, nontemplate control. This experiment was repeated independently three times with similar results.

[0076] FIG. 6A shows a schematic of the computational pipeline to identify species-specific bulk / single-cell RNA-seq reads.

[0077] FIG. 6B provides mapping rates of human genome in mEpiSCs determined by bulkRNA-seq. Asterisks indicate statistically significant differences: (***) P < 0.001 ; Fisher’s exact test.

[0078] FIG. 6C provides mapping rates of human genome in mEpiSCs co-cultured with P65KOhiPSCs determined by bulk RNA-seq. Asterisks indicate statistically significant differences: (***) P < 0.001 ; Fisher’s exact test.

[0079] FIG. 6D shows a schematic of human and mouse PSC co-culture in transwells and the following RNA-seq experimental setup.

[0080] FIG. 6E shows heatmap showing global expression profiles of human genes expressed in H9 hES cells and detected in mEpiSCs. Genes are sorted by expression levels from high to low in H9 hES cells. Log2-transformed expression levels were used to draw this plot.

[0081] FIG. 6F shows normalized abundance of human repeat elements in H9 hES cells (left) or mEpiSCs (right) aligned to the human genome (assembly HG38). Shown are repeat elements expressed in separately cultured H9 hES cells (Normalized Expression >20) and not detected in separately cultured mEpiSCs (Normalized Expression <20). Only reads uniquely assignable to a single repeat element type are shown. Heat maps were sorted on expression from high to low in H9 hES cells.

[0082] FIG. 6G shows normalized abundance of near-consensus human repeat elements in H9 hES cells (left) or mEpiSCs (right). Shown are least divergent repeat elements (full- length relative to consensus, <10 mismatches or indels) that were expressed in separately cultured H9 hES cells (Normalized Expression >20) and were not detected in separately cultured mEpiSCs (Normalized Expression <20). Heat maps were sorted on expression from high to low in H9 hES cells.

[0083] FIG. 6H shows expression of human repeat element classes in H9 hES cells under different culture conditions. Sep, Co-d1 , Co-d2, Co-d3, Sep-T and Co-T represent separate culture, co-culture on days 1 , 2, 3, separate culture in transwell and co-culture in transwell, respectively.

[0084] FIG. 6I shows expression of human retroelement families in H9 hES cells under different culture conditions. Sep, Co-d1 , Co-d2, Co-d3, Sep-T and Co-T represent separate culture, co-culture on days 1 , 2, 3, separate culture in transwell and co-culture in transwell, respectively.

[0085] FIG. 6J shows expression of Alu elements in H9 hES cells under different culture conditions. Sep, Co-d1 , Co-d2, Co-d3, Sep-T and Co-T represent separate culture, co-culture on days 1 , 2, 3, separate culture in transwell and co-culture in transwell, respectively.

[0086] FIG. 6K shows expression of evolutionarily young LINE1 elements in H9 hES cells under different culture conditions. Sep, Co-d1, Co-d2, Co-d3, Sep-T and Co-T represent separate culture, co-culture on days 1, 2, 3, separate culture in transwell and co-culture in transwell, respectively.

[0087] FIG. 6L provides normalized eGFP expression profile in mEpiSCs determined by bulk RNA-seq. Asterisks indicate statistically significant differences: (***) P < 0.001; Fisher’s exact test.

[0088] FIG. 6M shows the clustering of separately cultured and co-cultured mEpiSCs by scRNA-seq analysis. Each point represents one single cell, colored according to cluster, e, Percentage of separately cultured and co-cultured mEpiSCs in each cluster.

[0089] FIG. 6N provides violin plots showing the number of genes (left), UMIs (middle) and the percentage of mitochondria genes (right) per cell.

[0090] FIG. 60 shows percentage of separately cultured and co-cultured mEpiSCs in each cluster.

[0091] FIG. 6P provides mapping rates of human genome in mEpiSCs determined by scRNA-seq. Asterisks indicate statistically significant differences: (***) P < 0.001; Wilcoxon test. Cross-species doublets served as a negative control.

[0092] FIG. 6Q provides LIMAP visualization showing mapping rates of human genome in separately cultured (left) and co-cultured (right) mEpiSCs.

[0093] FIG. 6R provides LIMAP visualization showing eGFP+(red) and eGFP' (gray) mEpiSCs in separate culture (left) and co-culture (right).

[0094] FIG. 6S provides proportion of eGFP+mEpiSCs determined by scRNA-seq. Asterisks indicate statistically significant differences: (***) P < 0.001; Fisher’s exact test. Cross-species doublets served as a negative control.

[0095] FIG. 6T provides cumulative distribution showing proportion of eGFP+mEpiSCs with different thresholds. Asterisks indicate statistically significant differences: (**) P < 0.01 ; (***) P < 0.001; Fisher’s exact test; (N.S.) not significant.

[0096] FIG. 6U provides scatterplot showing global expression correlation of human genes detected in mEpiSCs and H9 hES cells determined by bulk RNA-seq and scRNA-seq. X-axis represents Pearson Correlation Coefficients whereas Y-axis represents P values. Triangles represent bulk RNA-seq datasets (indicated in the plot) or single-cell datasets. All datasets are summarized and shown as density plots along each axis.

[0097] FIG. 7A provides growth curves of H9 hES cells in separate culture (blue), co-culturewith WT mEpiSCs (red) and co-culture with MavsKOmEpiSCs (green). n=3; Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison.

[0098] FIG. 7B provides growth curves of H9 hES cells in separate culture (blue), co-culture with WT mEpiSCs (red) and co-culture with Ddx58K° mEpiSCs (green). n=3; Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison

[0099] FIG. 7C provides growth curves of H9 hES cells in separate culture (blue), co-culture with WT mEpiSCs (red) and co-culture with lfih1KOmEpiSCs (green). n=3; Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison

[0100] FIG. 7D provides growth curves of H9 hES cells in separate culture (blue), co-culture with WT mEpiSCs (red) and co-culture with IrlT*0mEpiSCs (green). n=3; Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison

[0101] FIG. 7E provides growth curves of H9 hES cells in separate culture (blue), co-culture with WT mEpiSCs (red) and co-culture with MavsKOTlr3KOmEpiSCs (green). n=3; Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison

[0102] FIG. 7F provides growth curves of H9 hES cells in separate culture (blue), co-culture with WT mEpiSCs (red) and co-culture with lrf3KOIrfT*0mEpiSCs (green). n=3; Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison

[0103] FIG. 7G provides growth curves of H9 hES cells in separate culture (blue), co-culture with WT mEpiSCs (red) and co-culture with Traded0mEpiSCs (green). n=3; Data are mean ± s.e.m. P values determined by one-way ANOVA with Dunnett’s multiple comparison

[0104] FIG. 8A provides a schematic showing the generation of ex vivo and in vivo humanmouse chimera using / Wavs-deficient mouse blastocysts.

[0105] FIG. 8B provides representative brightfield and fluorescence merged images of WT and / WavsKOmouse embryos cultured for 3 days (d3) and 5 days (d5) after blastocyst injection with hiPSCs. Scale bar, 100 pm.

[0106] FIG. 8C presents line graphs showing the percentages of eGFP+ mouse embryos at indicated time points during ex vivo culture after injecting hiPSCs into WT and MavsK° blastocysts, n = 3 (WT) and n = 3 ( / WavsKO) independent injection experiments. Data are mean ± s.e.m. P values determined by unpaired two-tailed t-test.

[0107] FIG. 8D provides a dot plot showing the percentages of eGFP+ E8.5-10.5 mouse embryos derived from injecting hiPSCs into WT and MavsK° blastocysts. Each dot represents one embryo transfer experiment, n = 4 (Mavs+I+), n = 4 (Mavs+I') and n = 7 (Mavs'1' ), independent experiments. Blue dots represent experiments using hiPSCs cultured inmTeSR medium. Pink dots represent experiments using hiPSCs cultured in 4CL medium.

[0108] FIG. 8E provides genomic PCR analysis of E8.5-10.5 mouse embryos derived from injecting hiPSCs into WT and MavsK° blastocysts. TPA25-Alu denotes a human-specific primer; PTGER2 was used as a loading control. HFF, HFF-hiPS cells. NTC, non-template control. This experiment was repeated independently three times with similar results.

[0109] FIG. 8F provides genomic qPCR analysis of E8.5-10.5 mouse embryos derived from injecting hiPSCs into WT and MavsKOblastocysts. Human mtDNA was normalized against a conserved element in both human and mouse mtDNA isolated from these embryos(maroon bars), a 10-fold serial dilution of human: mouse genomic DNAs was used as a standard(grey bars). Red dotted line highlights level equivalent to 1 : 104diluted standard.

[0110] FIG. 8G provides representative immunofluorescence images showing contribution of eGFP-labelled hiPSCs in E8.5 mouse embryos. Embryo sections were stained with antibodies against eGFP and lineage markers including PAX6 (ectoderm, top), aSMA (mesoderm, middle) and FOXA2 (endoderm, bottom). Scale bars, 100 pm. Images are representative of three independent experiments.

[0111] The drawing figures do not limit the present disclosure to the specific aspects disclosed and described herein. The drawing figures are not necessarily to scale, emphasis instead being placed on clearly illustrating principles of certain aspects of the present disclosure.DETAILED DESCRIPTION

[0112] The following detailed description references the accompanying drawings that illustrate various aspects of the present disclosure. The drawings and description are intended to describe aspects and aspects of the present disclosure in sufficient detail to enable those skilled in the art to practice the present disclosure. Other components can be utilized, and changes can be made without departing from the scope of the present disclosure. The following description is, therefore, not to be taken in a limiting sense.

[0113] The current disclosure is based, at least in part, on the surprising discovery that suppressing or manipulating the retinoic acid-inducible gene I (RIG-l)-like receptor (RLR) signaling pathway or related genes involved in inflammatory response to viral and non-host RNA in mouse embryos improves the feasibility of modifying the host embryos to boost interspecies chimerism of donor PSCs from humans, primates, and cows, providing a framework for generating human and non-human tissues and organs in animals that are more suitable for transplant.

[0114] The RLR signaling pathway represents one of the major RNA sensing systems in mammalian cells, which can be activated by viral and host-derived RNAs. RLR signaling participates in the maintenance of homeostatic genetic stability of cell populations and selfprotection. The pathway is regulated at a variety of levels ranging from autoregulation to ligand and co-factor interactions and post-translational modifications. Signaling is triggered by the binding of short (<2000 bp) single- or double-stranded RNA carrying an uncapped 5’ triphosphate and additional motifs such as poly-uridine rich RNA motifs to any of the RIG-like receptors for example RIG-1 (DDX58 gene), LPG2 or MDA5 (IFIH1 gene). Following activation RIG-l-like receptors, associates with DDX3X and phosphorylates interferon regulatory factors (IRFs), IRF3 and IRF7, as well as DDX3X. This activity allows subsequent homodimerization and nuclear translocation of the IRF3 leading to transcriptional activation of pro-inflammatory and antiviral genes including IFNB. To establish such an antiviral state, IKBKE (Jkke) forms several different complexes whose composition depends on the type of cell and cellular stimuli. Thus, several scaffolding molecules including I PS 1 / M A VS, TANK, AZI2 / NAP1 or TBKBP1 / SINTBAD can be recruited to the IKBKE-containing-complexes. RIG-1 and MDA5 recognize different RNA but share structural features that allows them to bind to mitochondrial antiviral-signaling protein (MAVS). Several additional genes are involved in either regulating or are downstream effectors of the RLR pathway. Table A provides NCBI gene reference for exemplary mouse and pig genes that are involved in the RLR pathway. This is not a comprehensive list, nor are mouse and pig the only hosts envisaged by the current disclosure. Additional non-human animal hosts are provided elsewhere in this application.Table 1 :

[0115] The current disclosure provides compositions and methods for producing viable human (humanized) and non-human chimeric cell populations, tissues, and organs in nonhuman host animal. In some aspects, the cells of the host in the chimera are modified to have a defective RLR or viral signaling pathway.I. Compositions

[0116] In some aspects, the current disclosure provides engineered pluripotent cell derived from a non-human animal, wherein the engineered pluripotent cell has a functionally defective “retinoic acid-inducible gene I (RIG-l)-like receptor” (RLR) signaling pathway. The RLR signaling pathway is a complex pathway that is regulated at a variety of levels ranging from autoregulation to ligand and co-factor interactions and post-translational modifications.

[0117] In some aspects, the engineered pluripotent cell is functionally defective in the RLR pathway. As used herein, the term “functionally defective” refers to a cell, wherein a gene, a protein and / or a pathway in the cell has a disrupted, reduced, inhibited activity and / or exhibits altered activity. In some aspects, the cell may be genetically disrupted for a gene, or one or more genes of a pathway. In some aspects, the engineered pluripotent cell may have a disrupted RLR gene. As used herein the terms “disruption,” “disrupting,” or “disrupted” refer to genetic modifications that alter the level of expression of a target gene. In some aspects, the disruption can be due to a deletion of at least one nucleotide within or near the target gene or a deletion of part or all of a target gene, as described above. In other aspects, the disruption also can be due to a substitution of at least one nucleotide and / or an insertion of at least one nucleotide within or near the target gene. In further aspects, the disruption can be due to an insertion of one or more exogenous polynucleotides within or near the target gene. In general, as used herein, disrupted expression refers to reduced or eliminated expression of the target gene. In some aspects, the disruption can be a reduced level of expression (e.g., express less than 30%, less than 25%, less than 20%, less than 10%, or less than 5% of the level of an unmodified cell). In some aspects, the disruption can be eliminated expression (e.g., no expression or an undetectable level of RNA and / or protein expression). In such aspects, the cell is considered to be a knockout for the gene of interest. Expression can be measured using any standard RNA-based, protein-based, and / or antibody-based detection method (e.g., RT- PCR, ELISA, flow cytometry, immunocytochemistry, western blotting, mass-spectrometry and the like). Detectable levels are defined as being higher that the limit of detection (LOD), which is the lowest concentration that can be measured (detected) with statistical significance by means of a given detection method. In some aspects, the current disclosure encompasses a pluripotent cell that has a gene disruption in a gene encodes an effector molecule (protein orRNA) that directly or indirectly impacts the RLR pathway or is a member of the pathway. In exemplary aspects, the pluripotent stem cell has a gene disruption in at least one of the Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7, Tradd, Trim25, Ifihl, NfaB genes or any combination thereof. In some aspects, the pluripotent cell is a gene knock out for at least one of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7, Tradd, Trim25, Ifihl, NfaB genes or any combination thereof. In some exemplary aspects, the pluripotent stem cell has a gene disruption in at least one of the Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7 genes or any combination thereof. In some aspects, the pluripotent cell is a gene knock out for at least one of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7, genes or any combination thereof.

[0118] In some aspects, the engineered pluripotent cell may be altered, inhibited, reduced, enhanced or lacking in a protein activity, wherein the protein directly or indirectly impacts the RLR pathway or is a member of the RLR signaling pathway. In some aspects, the engineered pluripotent cell may be reduced or diminished in the activity of one or more proteins of the RLR pathway or that directly or indirectly impact the RLR pathway. In some aspects, the engineered pluripotent cell may have less than 30%, or less than 25%, or less than 20%, or less than 10%, or less than 5% of the level of activity of an RLR pathway protein when compared to an unmodified cell. Methods of measuring activity of a protein are well known in the art and may include binding assays (for example: filter binding assay, Co-IP, Biacore, chromatographic binding assays, immunocytochemistry or electrophoresis techniques), assays to detect post translational modifications (for example: electrophoresis western blotting, mass spectrometry, ELISA, immunocytochemistry), or methods to measure enzyme kinetics. In some aspects, the pluripotent stem cell may exhibit an altered pattern of post- translational modification of one or more protein that impact, or are members of the RLR pathway. RLR members are regulated by, for example, ubiquitination and de-ubiquitination, phosphorylation, and / or SUMOylation. One or more of these processes may be altered to result in altered activity of RLR pathway. Exemplary assays to detect post-translational modifications are provided herein. In some aspects, the engineered pluripotent cell may have enhanced expression or activity of a protein or an RNA that negatively impacts or is an inhibitor of the one or more members of the RLR pathway. Endogenous negative regulators of RIG-I, MDA5 and MAVS functions include, but are not restricted, to LPG2, RHF125, RNF122, c-Cbl, A20USP3, USP21 , USP25, USP15, ARL16, ATG5-ATG12, NOD2, FAT10, SEC14L1 , ARL5B, TRIM13, TRIM 59, MARCH5, SMURF2, AIP4, NLRX1 , EZH2, PLK1 , TSPAN6, PPM1A, and PSMA7 as provided in Quicke et al. 2017 (https: / / doi.org / 10.1002 / eji.201646484). In some aspects, the current disclosure encompasses an engineered pluripotent cell exhibiting functional activation of one or more the proteins listed above. In some exemplary aspects, the engineered pluripotent cell is inhibited, reduced, or absent in the activity of MAVS, RIG-I,MDA5, IKK-epsilon, TBK1 , IRF3, and / or IRF7 proteins. In some aspects, the current disclosure also encompasses an engineered pluripotent wherein the engineered pluripotent cell is defective in IRF3 dimerization.

[0119] In some aspects, the current disclosure also encompasses engineered pluripotent cell that have been treated with an inhibitor of the RLR pathway. In some aspects, the inhibitor may be a small molecule, a drug, a nucleotide, a polynucleotide, a peptide, an aptamer, an antibody, or a polypeptide that binds to a protein of the RLR pathway. Examples of small molecule inhibitors of RLR pathway include, but are not limited to, BX795, Amlexanos, and MRT67307 (TBK1 / IKK-epsilon inhibitors). Examples of polynucleotide inhibitors include, but are not limited to, viral or synthetic dsRNA, siRNA, IcRNA, and miRNA. Several viral proteins are known the inhibit the RLR pathway including, but not limited to, influenza virus NS1 , Ebola virus VP35, and vaccinia virus E3. In some aspects, the current disclosure also encompasses, for example, an engineered pluripotent cell treated with an inhibitor of one or more of MAVS, RIG-I, MDA5, IKK-epsilon, TBK1 , IRF3, and IRF7 protein or gene expression to suppress the RLR signaling pathway.

[0120] In some aspects, the engineered pluripotent stem cell as disclosed herein may be a host cell. As used herein, the term “host cell” refers to a cell derived from or genetically analogous to a cell from an organism that may serve as a surrogate for the growth of the chimeric embryo. In some aspects, the host cell is engineered to boost interspecies chimerism when grown in the presence of a donor stem cell. In some aspects, the host cell is functionally defective for the RLR signaling pathway. As used herein, the donor cell is a cell from a human or non-human animal that is propagated with the host cell to form a chimeric embryo, tissue, or organ.

[0121] In some aspects, the current disclosure encompasses a population of cells comprising the host and donor cells as disclosed herein, and cell progenies thereof resulting from co-culture of these cells. In some aspects, the current disclosure also encompasses a cell culture comprising the host and donor cells as disclosed herein or progenies thereof.

[0122] In some aspects, the current disclosure encompasses a chimeric embryo comprising cells from two or more different mammalian species. In some aspects, at least one of the mammalian species (donor) is human and the other is a non-human animal (host). In some aspects, the one or more of the animal species is non-human (donor) and the other is a non- human from a different species (host). In some aspects, the human cells or non-human donor cells contained in the chimeric embryo are composed of any number of cell types, to include, but not limited to embryonic cells, embryonic stem cells, induced pluripotent stem cell, adult stem cells, cord blood cells or a variant, or a progeny thereof or a mixture of cell types. Insome aspect, the host cell contained in the embryo are composed of any number of pluripotent cell types, to include, but not limited to embryonic cells, embryonic stem cells, epiblast stem cells, induced pluripotent stem cells or a mixture and variants or progenies thereof. In some aspects, the current disclosure also encompasses a chimeric embryo as provided herein, where the one or more endogenous genes of the non-human embryo responsible for the development of one or more endogenous organs or tissues have been disrupted by Transcription Activator-Like Effector Nucleases (TALENS), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), CRISPR associated protein 9 (Cas9), Zinc Finger Nucleases (ZFNs), molecules encoding site-specific endonucleases, synthetic artificial chromosomes, RecA-gal4 fusions, RNAi, CRISPRi, or any combination thereof.

[0123] In some aspects, the host as disclosed herein can be any non-human organism. In some aspects, the host is a vertebrate. In some aspects the host is a mammal. In some aspects, the host is a rodent, for example a mouse, rat, hamster. In some aspects, the host is an ovine, for example a sheep, or a lamb. In some aspects, the host is a bovine, for example a cow, ox, bison. In some aspects, the host is a porcine, for example a pig.

[0124] The cells composing the chimeric embryo may contain one or more additional genetic modifications. Such modifications include genetic disruptions or addition of elements into the donor or the host cell. In some aspects, any one of the host or donor cells may be functionally defective in one or more gene products. In some aspects, any one of the host or donor cells may have enhanced functionality of one or more endogenous gene products. In some aspects, any one of the host or donor cells may be engineered to have enhanced functionality of one or more exogenous genes

[0125] In some aspects, the present disclosure also encompasses any cell line developed from the chimeric embryo. In addition, the present invention includes any tissue, organ or animal and any descendant of an animal developed from the chimeric embryo.

[0126] In certain aspects, the current disclosure also encompasses, mammalian organs or tissues isolated from a chimeric mammal comprising cells derived from at least a host mammal and a donor mammal, wherein the organ or tissue is derived from a stem cell (for example an iPSC) cell from the donor mammal, wherein the host and donor mammal are from different species. In some aspects, the organ or tissue comprises at least one of the group consisting of liver, kidney, pancreas, hematopoietic stem cells, spleen, bone marrow, heart, lung, skin, cornea, eye, spinal cord, uterus, intestine, heart valve, bone, cartilage, tendon, ligament, lymphatic vessel, and blood vessel. In some aspects, the host is selected from the group consisting of mouse, rat, rabbit, guinea pig, human, cow, pig, horse, goat, and sheep. In some aspects, the donor mammal is selected from the group consisting of human, mouse, rat, rabbit,guinea pig, cow, pig, horse, goat, and sheep. In some aspects, the donor mammal is a human. In some aspects, the host mammal is a mouse or a pig. In some aspects, at least a cell of the host mammal is functionally defective for the RLR signaling pathway. In some aspects, the cell of the host mammal has a genetic modification in at least one of the genes that impact or are part of the RLR pathway. In some aspects, the genetic modification disrupts at least one gene selected from the group consisting of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, and lrf7.

[0127] In certain aspects, provided herein are chimeric mammals comprising cells derived from at least a host mammal and a donor mammal, wherein the cells from the host mammal comprise cells derived from a blastocyst comprising a genetic modification at one or more loci and the cells from the donor mammal comprise cells derived from a stem cell, for example an induced pluripotent stem cell (iPSC) and from at least one organ or tissue, wherein the host and donor mammal are different species. In some aspects, the host mammal is selected from the group consisting of mouse, rat, rabbit, guinea pig, cow, pig, horse, goat, and sheep. In some aspects, the host mammal is a mouse or a pig. In some aspects, the host mammal is a mouse. In some aspects, the host mammal is a pig. In some aspects, the donor mammal is selected from the group consisting of human, mouse, rat, rabbit, guinea pig, human, cow, pig, horse, goat, and sheep. In some aspects, the donor mammal is a human. In some aspects, the chimeric mammal has a percentage chimerism as a ratio between the donor mammal and the host mammal of less than 10%. In some aspects, the organ or tissue comprises at least one of the group consisting of liver, kidney, pancreas, hematopoietic stem cells, spleen, bone marrow, heart, lung, skin, cornea, eye, spinal cord, uterus, intestine, heart valve, bone, cartilage, tendon, ligament, lymphatic vessel, and blood vessel. In some aspects, the organ or tissue is chimeric. In some aspects, the organ or tissue has a percentage chimerism as a ratio between the donor mammal and the host mammal of at least 10%. In some aspects, the organ or tissue has a percentage chimerism as a ratio between the donor mammal and the host mammal of at least 50%. In some aspects, the organ or tissue has a percentage chimerism as a ratio between the donor mammal and the host mammal of at least 90% to 99%. In some aspects, the genetic modification disables organogenesis of an organ or tissue. In some aspects, at least a cell of the host mammal is functionally defective for the RLR signaling pathway. In some aspects, the cell of the host mammal has a genetic modification in at least one of the genes that impact or are part of the RLR pathway. In some aspects, the genetic modification disrupts at least one gene selected from the group consisting of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, and Irf7.

[0128] Chimeric tissue, organ or animals as described herein are characterized by having a percentage chimerism as a ratio between the donor and the host. In some aspects, the percentage chimerism is less than 40%. In some aspects, the percentage chimerism is lessthan 30%. In some aspects, the percentage chimerism is less than 20%. In some aspects, the percentage chimerism is less than 10%. In some aspects, the percentage is less than 5%. In some aspects, the percentage chimerism is less than 1 %. In some aspects, the percentage chimerism is more than 1%. In some aspects, the percentage chimerism is more than 5%. In some aspects, the percentage chimerism is more than 10%. In some aspects, the percentage chimerism is more than 20%. In some aspects, the percentage chimerism is more than 30%. In some aspects, the percentage chimerism is more than 40%.

[0129] In some aspects, the organ or tissue has a percentage chimerism as a ratio between the donor and the host of at least 10%. In some aspects, the organ or tissue has a percentage chimerism as a ratio between the donor and the host of at least 50%. In some aspects, the organ or tissue has a percentage chimerism as a ratio between the donor and the host of at least 90%. In some aspects, the organ or tissue has a percentage chimerism as a ratio between the donor and the host of at least 95%. In some aspects, the organ or tissue has a percentage chimerism as a ratio between the donor and the host of at least 99%.II. Methods and uses

[0130] In some aspects, the current disclosure also encompasses a method of producing a human or non-human cell population, a tissue, and / or an organ in a non-human animal of a different species, the method comprising microinjecting a human or non-human animal stem cell in a non-human blastocyst of a different species, thereby generating a chimeric embryo, wherein the non-human blastocyst is functionally defective for the “retinoic acid-inducible gene I (RIG-l)-like receptor” (RLR) signaling pathway. In some aspects, the non-human blastocyst is functionally defective for any one of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7 or any combination thereof. Broadly, in some aspects, the method isolating and injecting a blastocyst of a host mammal with at least one stem cell (SC), for example a iPSC, from a donor mammal to form a chimeric blastocyst; transferring the chimeric blastocyst into a pseudo-pregnant host mammal which may or may not be the same as the host mammal from which the blastocyst was isolated; and obtaining a chimeric mammal comprising the mammalian organ or tissue; wherein the host and donor mammal are different species, and wherein the host mammal is genetically modified at one or more loci in at least one cell and the organ or tissue is derived from iPSC from the donor mammal.

[0131] In some aspects, methods of culturing a mammalian organ or tissue comprise creation of a chimeric blastocyst. Chimeric blastocysts are created by methods known in the art, for example, injection of a donor stem cell (for example an ESC or an iPSC), for example 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 iPSCs from the donor mammal are injected into the blastocyst of the host mammal. In some aspects, 1-5 iPSCs fromthe donor mammal are injected into the blastocyst of the host mammal. In some aspects, 1- 10 iPSCs from the donor mammal are injected into the blastocyst of the host mammal. In some aspects, 1-15 iPSCs from the donor mammal are injected into the blastocyst of the host mammal. In some aspects, 1-5, 1-10, 1-15, 1-20, 5-10, 5-15, or 5-20 iPSCs from the donor mammal are injected into the blastocyst of the host mammal. In some aspects, the blastocyst of the host mammal is injected between days 4 and 7 post-fertilization, for example on day 4, 5, 6, or 7 post-fertilization. In some aspects, the blastocyst of the host mammal is injected between days 3 and 8, days 4 and 7, days 5 and 6, days 4 and 8, or days 3 and 7 postfertilization. In some aspects, the chimeric blastocyst is transferred 2 to 30 hours after injection, for example 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28 ,29, or 30 hours after injection. In some aspects, the chimeric blastocyst is transferred 2 to 5, 5 to 10, 10 to 15, 15 to 20, 20 to 25, or 25 to 30 hours after injection. In some aspects, once a chimeric embryo is produced it can be propagated for varying periods of time in culture, where it may undergo a series of developmental steps. Methods of culturing mammalian embryos are known in the art. For some uses, the embryos can be brought to term, forming the chimeric animals of the invention.

[0132] In the case of mammalian chimeric embryos, progression through later stages, and completion of development to term, requires implantation and placentation, and therefore introduction into the uterus of a hormonally prepared “pseudopregnant” female. The foster mother can be of the same species as the embryo or one of its cellular components but need not be. In some aspects the chimeric embryos, like their non-chimeric counterparts, can be cryopreserved for later use.

[0133] In some aspects, the current disclosure also encompasses a method of generating a chimeric embryo, the method comprising: administering to a zygote of a non-human embryo, a composition comprising an RNA guided nuclease and a sgRNA targeting one or more of a gene encoding an effector that impacts or is part of the RLR pathway; culturing the embryo to a blastocyst stage; microinjecting stem cell from a human or a non-human animal from a different species, into the blastocyst to generate a chimeric embryo; transferring the chimeric embryo to a surrogate mother, such that the chimeric embryo comprises non-human cell and human cells, or non-human cells from different species. In some aspects, the RNA guided nuclease and a sgRNA target any one of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7 or any combination thereof, thereby causing the cell to be defective in one or more of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7 or any combination thereof. Exemplary sgRNA target sequences for targeting Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, and !rf7 are provided herein in Table 2, however any sgRNA targeting Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7 or any gene impacting RLR pathway, wherein the disruption improves propagation and survival of donor cells inchimeric embryos are envisaged herein. Thus, in some aspects, the sgRNA targets a nucleic acid sequence at least about 80% identical to any one of SEQ ID NOS: 1-7. In some aspects, the sgRNA comprises a nucleic acid sequence at least about 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOS: 1-7.

[0134] Additional method of disrupting the genes of the RLR pathway are also encompassed in the current disclosure. Thus, the engineered pluripotent cell as disclosed herein can be modified by any method known in the art. In some aspects, the term “genetically modified” or “modified cell” refers to a cell in which the nuclear, organellar or extrachromosomal nucleic acid sequences of a cell has been transformed, modified or transduced using recombinant DNA technology to comprise a heterologous nucleic acid molecule, and is used interchangeably with “engineered cell,” “transformed cell,” and “transduced cell.” In one aspect, a genetically modified cell as disclosed herein expresses a protein encoded by a nucleic acid molecule engineered in such manner to contain an insertion of at least one nucleotide, a deletion of at least one nucleotide, and / or a substitution of at least one nucleotide in a sequence encoding at least one heterologous protein. “Engineered cells” refers herein to cells having been engineered, e.g., by the introduction of an exogenous nucleic acid sequence as defined herein. Such a cell has been genetically modified for example by the introduction of for example one or more mutations, insertions and / or deletions in the endogenous gene and / or insertion of a genetic construct in the genome. The modification may have been introduced using recombinant DNA technology. An engineered cell may refer to a cell in isolation or in culture. Engineered cells may be “transduced cells” wherein the cells have been infected with e.g., a modified virus, for example, a retrovirus may be used but other suitable viruses may also be contemplated such as lentiviruses. Non-viral methods may also be used, such as transfections. Engineered cells may thus also be “stably transfected cells” or “transiently transfected cells”. Transfection refers to non-viral methods to transfer DNA (or RNA) to cells such that a gene is expressed. T ransfection methods are widely known in the art, such as calcium phosphate transfection, PEG transfection, and liposomal or lipoplex transfection of nucleic acids. Such a transfection may be transient but may also be a stable transfection wherein cells can be selected that have the gene construct integrated in their genome. In some cases, genetic engineering systems such as CRISPR or Argonaute may be utilized to design engineered cells that express a polypeptide described herein. A variety of enzymes can catalyze insertion of foreign DNA into a host genome. Non-limiting examples of gene editing tools and techniques include CRISPR, TALEN, zinc finger nuclease (ZFN), meganuclease, Mega-TAL, and transposon-based systems. A CRISPR system can be utilized to facilitate insertion of a polynucleotide sequence encoding a membrane protein or acomponent thereof into a cell genome. For example, a CRISPR system can introduce a double stranded break at a target site in a genome. CRISPR nucleases are part of a range of nucleases that belong to the category of “RNA guided nucleases”. There are at least five types of CRISPR systems which all incorporate RNAs and CRISPR-associated proteins (Cas). Types I, III, and IV assemble a multi-Cas protein complex that is capable of cleaving nucleic acids that are complementary to the crRNA. Types I and III both require pre-crRNA processing prior to assembling the processed crRNA into the multi-Cas protein complex. Types II and V CRISPR systems comprise a single Cas protein complexed with at least one guiding RNA.

[0135] It will be apparent to those skilled in the art that various modifications and variations can be made in the manner in which the chimeric embryo is created and propagated, without departing from the scope or spirit of the present invention. For example, substantial research is currently in progress toward the development of artificial uteri for various species, both mammalian and non-mammalian. In addition, various in vitro techniques have been and continue to be investigated that could potentially sustain life in vitro and allow for the propagation and further development of embryonic cells. By means of further example, alternatives to the three methods of preparing the embryo discussed above may also be developed. Thus, it is intended that the present invention cover all of the modifications and variations of the invention, provided they come within the scope of the appended claims and their equivalents.

[0136] The chimeric cells, culture, tissues, organs, and animals as disclosed herein can be put to use in a wide range of scenarios.

[0137] One use of chimeric embryos containing human cells would be in the scientific field of developmental biology, where it is of interest to determine the factors which regulate the differentiation of human embryonic cells, and their assembly into tissues and organs. Social and legal constraints prevent the observation of, and experimentation on, human embryos at advanced stages of development. In contrast, chimeric embryos containing human cells can be followed in culture or harvested from the uteri of non-human foster mothers, and subjected to histological and experimental analysis. The human cells can be transfected with a “reporter gene” by which their fate can be followed during subsequent development.

[0138] Chimeric embryos containing human cells will be useful in the fields of teratology and toxicology. One of the objects of the present invention is to create model systems to permit the clinical testing, or simple assays, of compounds on human cells or non-human mammals (for example veterinary animals), without risk to the subjects. It is well known in the art that many drugs that are highly efficacious in animal models, may have little or no effect in humans. Unfortunately, some of these compounds may actually have deleterious effects whenadministered to humans. It is an important object of the invention to create model systems which will not place humans or other donor animals at risk during clinical testing of these compounds.

[0139] Many drugs available today, and many compounds in drug development, suffer from the “risk versus benefit” dilemma. The compound has proven efficacy, but also possesses unavoidable, potentially serious, side effects. It is important to determine at which dose the risk that the compound poses is greater than the benefit it provides. Many of the “risk versus benefit” drugs have relied on inadequate animal models to determine the “risk” factor of the equation. The present invention allows a more accurate determination of the compound's effect on human and non-human animal cells and / or tissue without the need to expose subjects to trials with new and unknown compounds. An additional advantage of the present invention is the ability to more accurately determine the proper dose rate in human and non- human mammalian cells and / or tissues of the high-risk compounds.

[0140] Chimeric embryos and animals containing human or non-human cells would be useful in the scientific field of physiology, in which response of tissues to various stimuli and treatments is studied. For example, organs like heart containing human cells or non-human mammalian cells, would provide as yet unobtainable information on the ability of heart cells to produce stress proteins in response to external stimuli. Protein production in heart tissue has been shown to be highly variable among species. The present invention is an invaluable model in the study the effects of various stimuli on human heart tissue.

[0141] Chimeric animals would also find use in the field of transplantation medicine, which suffers from a shortage of donor organs. Although attempts have been made to transplant baboon hearts and bone marrow into humans, and pig hearts into primates, rejection is usually swift unless complex drug treatment protocols accompany the transplantation, or genetically modified organs are used. Even these procedures can only guarantee limited success at the present time.

[0142] Therefore, contemplated herein are methods of treating a subject in need of an organ or a tissue transplant using cultured mammalian organs described herein. Cultured mammalian organs herein have the advantage that they are derived from an iPSC or ESC, such as a human iPSC or ESC, and they are cultured or grown in a chimeric mammal. Therefore, cultured mammalian organs are customizable and are not dependent on organ donor volunteers. Additional advantages of mammalian organs herein are suitability for treatment of each individual as the iPSC or ESC, from which the organ or tissue is derived, is obtainable from the individual in need of organ or tissue transplant and the organ or tissue is HLA matched to the individual receiving the transplant.

[0143] Methods of treating an individual in need of an organ or a tissue transplant comprise administration or transplant of a tissue or organ described herein. Organs for transplant are contemplated to include, but are not limited to, liver, kidney, pancreas, hematopoietic stem cells, spleen, bone marrow, heart, lung, skin, cornea, eye, spinal cord, uterus, intestine, heart valve, bone, cartilage, tendon, ligament, central nervous system tissue, peripheral nervous system tissue, lymphatic vessel, or blood vessel.

[0144] Individuals in need of transplant include, but are not limited to, individuals diagnosed with or suffering from a disease including but not limited to liver failure, liver cirrhosis, kidney failure, diabetes, cancer, severe combined immunodeficiency syndrome, aplastic anemia, congenital neutropenia, sickle cell anemia, thalassemia, intestine failure, ruptured spleen, heart failure, coronary artery disease, congenital heart disease, burn, skin infection, skin cancer, venous ulcer, pressure ulcer, diabetic ulcer, wound, macular degeneration, glaucoma, retinoblastoma, complete paraplegia, complete tetraplegia, anterior cord syndrome, central cord syndrome, posterior cord syndrome, Brown-Sequard syndrome, Cauda Equina Lesion, congenital uterine disease, female infertility, intestinal failure, parenteral nutrition disorder, chronic obstructive pulmonary disease, emphysema, idiopathic pulmonary fibrosis, cystic fibrosis, idiopathic pulmonary hypertension, alpha 1-antitrypsin deficiency, bronchiectasis, sarcoidosis, keratoconus, Fuchs' dystrophy, cornea thinning, cornea scarring, cornea clouding, cornea swelling, corneal ulcer, bone cancer, bone fracture, rheumatoid arthritis, osteoarthritis, ruptured tendon, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, aging, dementia, neurodegeneration, multiple sclerosis, congenital vascular disorder, and atherosclerosis.

[0145] Organs derived from iPSC or ESCs for treatment of individuals are derived from the same individual in need of a transplant. iPSC or ESCs are also contemplated to be derived from a first-degree relative. It is also contemplated that iPSC or ESCs are derived from an unrelated HLA-matched individual. An HLA-matched individual is understood to be an individual who matches HLA-type with the individual in need of a transplant at a minimum of five of five loci. It is also understood that an HLA-matched individual matches HLA-type with the individual in need of a transplant at a minimum of ten out of ten loci. In some aspects, an HLA-matched individual is a partial match, matching the HLA-type with the individual in need of a transplant at four out of five, eight out of ten, or nine out of ten loci.

[0146] Contemplated herein are novel methods of testing safety and efficacy of a drug, for example using a chimeric mammal described herein to more accurately determine the safety and efficacy of a therapeutic drug prior to testing in human subjects. Limitations in current pre- clinical safety and efficacy testing of a drug are that the target organ or tissue for the drug in the test organism is a different species than the intended target organ or tissue. For example,testing a drug that targets the kidney for therapy can currently be tested in a model organism, but differences in the kidney of a model organism compared to a human subject can lead to inaccurate results. Therefore, it is desirable to test a drug in a more relevant model organism, such as a chimeric mammal described herein, where the target organ or tissue is derived from a human and more accurate results will be achieved in such testing. Some such methods of testing safety and efficacy include a method of testing the safety and efficacy of a drug comprising administering the drug to any of the chimeric mammals described herein and measuring toxicity and therapeutic benefit in the chimeric mammal. In some aspects, the toxicity comprises at least one of body weight, food consumption, histopathology, immunogenicity, autoimmunity, genotoxicity, nephropathy, hepatopathology, neuropathology, and carcinogenesis. In some aspects, the therapeutic benefit comprises an intended effect of the drug administered.

[0147] Also contemplated herein are in vitro methods of testing safety and efficacy. In some aspects, the method of testing the safety and efficacy of a drug comprises contacting the drug to any of the mammalian organs described herein and measuring toxicity and in vitro therapeutic benefit. In some aspects, the toxicity comprises at least one of cellular apoptosis, histopathology, and genotoxicity. In some aspects, the in vitro therapeutic benefit comprises an intended effect of the drug administered.III. Terminology

[0148] The phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting. For example, the use of a singular term, such as, “a” is not intended as limiting of the number of items. Also, the use of relational terms such as, but not limited to, “top,” “bottom,” “left,” “right,” “upper,” “lower,” “down,” “up,” and “side,” are used in the description for clarity in specific reference to the figures and are not intended to limit the scope of the present inventive concept or the appended claims.

[0149] Further, as the present inventive concept is susceptible to aspects of many different forms, it is intended that the present disclosure be considered as an example of the principles of the present inventive concept and not intended to limit the present inventive concept to the specific aspects shown and described. Any one of the features of the present inventive concept may be used separately or in combination with any other feature. References to the terms “aspect,” “aspects,” and / or the like in the description mean that the feature and / or features being referred to are included in, at least, one aspect of the description. Separate references to the terms “aspect,” “aspects,” and / or the like in the description do not necessarily refer to the same aspect and are also not mutually exclusive unless so stated and / or except as will be readily apparent to those skilled in the art from the description. For example, a feature, structure, process, step, action, or the like described in one aspect may also beincluded in other aspects but is not necessarily included. Thus, the present inventive concept may include a variety of combinations and / or integrations of the aspects described herein. Additionally, all aspects of the present disclosure, as described herein, are not essential for its practice. Likewise, other systems, methods, features, and advantages of the present inventive concept will be, or become, apparent to one with skill in the art upon examination of the figures and the description. It is intended that all such additional systems, methods, features, and advantages be included within this description, be within the scope of the present inventive concept, and be encompassed by the claims.

[0150] Any term of degree such as, but not limited to, “substantially” as used in the description and the appended claims, should be understood to include an exact, or a similar, but not exact configuration. For example, “a substantially planar surface” means having an exact planar surface or a similar, but not exact planar surface. Similarly, the terms “about” or “approximately,” as used in the description and the appended claims, should be understood to include the recited values or a value that is three times greater or one third of the recited values. For example, about 3 mm includes all values from 1 mm to 9 mm, and approximately 50 degrees includes all values from 16.6 degrees to 150 degrees. For example, they can refer to less than or equal to ± 5%, such as less than or equal to ± 2%, such as less than or equal to ± 1 %, such as less than or equal to ± 0.5%, such as less than or equal to ± 0.2%, such as less than or equal to ± 0.1 %, such as less than or equal to ± 0.05%.

[0151] The terms “comprising,” “including” and “having” are used interchangeably in this disclosure. The terms “comprising,” “including” and “having” mean to include, but not necessarily be limited to the things so described.

[0152] Lastly, the terms “or” and “and / or,” as used herein, are to be interpreted as inclusive or meaning any one or any combination. Therefore, “A, B, or C” or “A, B, and / or C” mean any of the following: “A,” “B,” or “C”; “A and B”; “A and C”; “B and C”; “A, B, and C.” An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive.

[0153] The terms "nucleic acid”, "nucleic acid molecule”, and "polynucleotide” are used interchangeably herein. The terms “nucleic acid encoding . . .”, or “nucleic acid molecule encoding . . . " should be understood as referring to the sequence of nucleotides which encodes a polypeptide.

[0154] A polynucleotide described herein may comprise one or more nucleic acids each encoding a polypeptide, operably linked to (i.e. , in a functional relationship with) one or more regulatory sequences, such as a promoter. Such a polynucleotide may alternatively be referred to herein as a "nucleic acid construct” or "construct”. As used herein, the term“operably linked” refers to a functional linkage between a promoter or other regulatory element and an associated transcribable DNA sequence or coding sequence of a gene (or transgene), such that the promoter, etc., operates to initiate, assist, affect, cause, and / or promote the transcription and expression of the associated transcribable DNA sequence or coding sequence, at least in certain tissue(s), developmental stage(s) and / or condition(s).

[0155] “Humanized” as used herein refers to an organ or tissue harvested from a nonhuman animal whose protein sequences and / or genetic complement are modified to increase the organ’s or tissue’s similarity to a human organ or tissue.

[0156] “Organ” as used herein refers to a collection of tissues joined in a structural unit to serve a common function.

[0157] “Tissue” as used herein refers to a collection of similar cells that together carry out a specific function.

[0158] The term “blastocyst” is used broadly herein to refer to embryos from two cells to about three weeks.EXAMPLES

[0159] In some aspects, the current disclosure is a result of extensive experimentation to determine pathways that favor the growth and proliferation of mouse epiblast stem cells (mEpiSC) in comparison to human, monkey or cattle stem cells (hSC) in chimeric cultures. These experiments provided the surprising result that the “retinoic acid-inducible gene I (RIG- l)-like receptor” (RLR) signaling pathway plays a key role in supporting growth and proliferation of host (for example, mouse) versus the non-host (for example, human) stem cells. Therefore, the pathway poses a problem for any attempt to generate inter-species chimeras. Experiments were conducted to inactivate one of more members of the RLR pathway in the host cells before establishment of the chimera. Provided herein are examples that explore, and provide evidence that show that host cells with inactivated RLR are better suited for establishing chimeric cell population both ex vivo and in vivo.

[0160] The following examples are included to demonstrate preferred aspects of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of the present disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific aspects which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the present disclosure.Example 1 : MethodsAnimals and ethical review

[0161] CD-1 (ICR), C57BL / 6 and BDF1 mice were purchased from Envigo (Harlen), Charles River, or Jackson Laboratory. Homozygous Mavs knockout mice were kindly gifted from Prof. Zhijian J. Chen. Mice were housed in 12-hr light / 12-hr dark cycle at 22.1-22.3°C and 33-44% humidity. All procedures related to animals were performed in accordance with the ethical guidelines of the University of Texas Southwestern Medical Center (UTSW). Animal protocols were reviewed and approved by the UTSW Institutional Animal Care and Use Committee (IACUC) before any experiments were performed (Protocols #2018-102430). All experiments followed the 2021 Guidelines for Stem Cell Research and Clinical Translation released by the International Society for Stem Cell Research (ISSCR). All human-mouse ex vivo and in vivo interspecies chimeric experimental studies were reviewed and approved by UT Southwestern Stem Cell Oversight Committee (SCRO) (registration 14).Primed PSC culture

[0162] Human ES cell line H9 (WA09) were obtained from WiCell and authenticated by short tandem repeat (STR) profiling. HFF-hiPS cells, mouse EpiSCs, rhesus macaque ES cells, and bovine ES cells were generated by known methods. Human primed PSCs were either cultured on plates coated with Matrigel (BD Biosciences) in mTeSRI medium (STEMCell Technologies) or on MEFs in NBFR medium, which contains DMEM / F12 (Invitrogen) and Neurobasal medium (Invitrogen) mixed at 1 :1 ratio, 0.5* N2 supplement (Invitrogen), 0.5* B27 supplement (Invitrogen), 2 mM GlutaMax (Gibco), 1 * nonessential amino acids (NEAA, Gibco), 0.1 mM 2-mercaptoethanol (Sigma-Aldrich), 20 ng mL-1FGF2 (PeproTech), 2.5 pM IWR1 (Sigma-Aldrich), and 1 mg mL-1BSA (low fatty acid, MP Biomedicals). Mouse, rhesus and bovine primed PSCs were all cultured on MEFs in NBFR medium. Primed PSCs cultured in NBFR medium were passaged using TrypLE (human, rhesus and bovine) at 1 :10 split ratio every 4-5 days, and 1 :30 split ratio (mouse) every 3-4 days. Human primed PSCs cultured in mTeSRI medium on Matrigel were passaged every five days using Dispase (STEMCell Technologies) at 1 :10 split ratio.Generation of fluorescently labelled PSCs

[0163] pCAG-IP-mKO and pCAG-IP-eGFP were used to label PSCs. For generating nucleus labelled PSCs, piggyBac transposon vectors expressing eGFP-H2B and mScarlet- H2B were used. In brief, 3 pg piggyBac-eGFP-H2B or piggyBac-mScarlet-H2B plasmids were transfected together with 1 pg piggyBac transposase plasmid into 1 x io6-2 x 106dissociated PSCs using NEPA21 electroporator (Nepa Gene) following the protocol recommended by themanufacturer. eGFP+or mScarlet+ cells were collected by FACS at 48 h after transfection and replated. Single clones with stable fluorescence were manually picked between 7 and 14 days and further expanded clonally.Interspecies PSC co-culture

[0164] PSCs from different species were seeded onto MEF-coated plates and either cultured separately or mixed at different ratios for co-cultures in NBFR medium. The seeding ratio and density were empirically tested and decided on the basis of cell growth rate. For 5- days-co-culture assays between human-mouse, rhesus-mouse and bovine-mouse PSCs, cells were seeded at a 4:1 ratio at a density of 1.25 x 104cells cm-2. For human-mouse 3- days-co-culture, seeding density was increased to 1.875 x 104cells cm-2but seeding ratio was kept at 4: 1 . For transwell co-culture experiments, Millipore T ranswell 0.4 pm PET hanging inserts (Millicell, MCH12H48) were placed into 12-well plates. Then coverslips were placed into both the upper insert and the bottom well, mEpiSCs and hES cells were seeded on the top insert and bottom well, respectively. At each of the indicated time points, cell concentration was manually counted and calculated, and the percentages of each cell line were determined using FACSCalibur system (BD Bioscience). Total cell numbers (tN) for each species in cocultures or separate cultures were determined by multiplying total cell volume (V) with cell concentration (CC) and percentage (P). tN = V x CO x p. Cell density (cells cm-2) was calculated by dividing the total cell number by the surface area.Micropattern imaging and automated cell counting

[0165] The micropattern-based imaging was performed on CYTOO micropattern plates (CYTOOplate 96w Custom A700-P400 A). Specifically, the micropattern wells were coated with 0.5% (v / v) Matrigel at 4 °C, O / N, and MEF feeder cells were seeded in each well one day before the experiment starts. On the day the experiment starts (day 0), unattached MEF feeder cells were washed out and then eGFP-H2B labeled WT or MavsK° mEpiSCs and / or mScarlet- H2B labeled H9 hES cells were seeded into each well separately or mixed as indicated in the main text. On days 1-3, individual micropattern colonies were tracked by live imaging. Cells were then fixed and DAPI stained on day 3. Fluorescence imaging was performed on Nikon CSLI-W1 SoRa spinning disk confocal microscope with 20x (0.75 NA, WD1 (air)) objective. Z- stacks were acquired for each micropattern colony with 1 pm step, approximately 30-75pm range in Z was covered depending on the thickness of each colony. Imaging experiments were repeated at least three times with similar results. Cell counting was performed on Imaris (version 9.1 , Oxford Instruments) by using the SPOTS function. Same parameters for computing of human and mouse cells were applied.Time-lapse imaging and analysis

[0166] For time-lapse imaging of co-cultures using bowtie-shaped microwells, the photoresist template was fabricated by negative photolithography. The chrome mask was manufactured by the University of Texas at Dallas, and KMPR 1050 photoresist (Microchem, Westborough, MA) was used following the manufacturers’ instructions. Silicon (PDMS) molds were fabricated from Sylgard 184 Silicon Elastomer (#24236-10 - Electron Micro Sciences, Hatfield, PA). These PDMS stamps were sealed to glass coverslips with features-side down. A solution of 1% Agarose (#MIDSCI500 - Midsci, St. Louis, MO) in distilled water (C = 10 mg / mL) was heated to 100 °C until the solution became crystal clear. Subsequently, 600 mL of this 1% agarose solution was mixed with 400 mL of 100% ethanol, and a drop of this hot agarose / ethanol solution was pipetted against the side of the PDMS stamp to perfuse through the gaps formed between the silicon mold and the coverslip. After several hours, the PDMS stamp was carefully removed from the coverslip with fine-tipped forceps. However, the agarose layers tend to detach from the glass coverslip in long-term cell culture conditions (37 °C, 5% CO2). To solve this issue, the glass coverslips were precoated with an ultra-thin layer of polystyrene dissolved in chloroform (0.2 mg mL-1). A small drop of this mixture was added onto each coverslip, which was then spin-coated (-100 rpm for 1-2 donors followed by -3,000 rpm for 4-6 donor) to spread the polystyrene uniformly. Finally, the coverslips were exposed to UV light in a tissue culture hood for 1 hour to graft the polystyrene layer prior to the addition of the agarose / ethanol solution. To setup an experiment, the coverslips holding the polystyrene / agarose layers were incubated with fibronectin in PBS (50 mg mL-1) for 1 h at 37 °C, rinsed twice with PBS and dried several minutes before cells were seeded on the coverslips in culture media. After 48 hours of incubation, the coverslips with the cells were placed in a 37 °C / 5% CO2 chamber for live imaging. The samples were imaged using a Leica SP8 inverted confocal microscope, equipped with a 40x oil objective. A z-stack of 8 images (1 ,024 x 1 ,024 pixels, z-step size 2.5 pm) was recorded every 10 min for 24 h. Fluorescent signals (488 and 561 nm) were collected sequentially to avoid any bleed-through using a 100 Hz scan rate. Imaged (NIH, 64-bit Java 1.8.0_172) was used to produce a maximum intensity projection of each z-stack. All the resulting 2D images were assembled into time-lapse videos.CRISPR knockout

[0167] All single guide RNAs (sgRNAs) used in this study were designed by using the online software (MIT CRISPR Design Tool: http: / / crispr.mit.edu). The sequences of sgRNA targets are included in Table 2.Table 2:

[0168] sgRNAs were cloned into the pSpCas9(BB)-2A-eGFP (Addgene, PX458) plasmid by ligating annealed oligonucleotides with Bbsl-digested vector. 4 pg plasmid carrying the specific sgRNA was then transfected into 1 x 106- 2 x 106dissociated mEpiSCs using NEPA21 electroporator (Nepa Gene). For generating large genomic fragment deletion at specific gene locus, two sgRNA plasmids were transfected simultaneously. eGFP+cells were collected by FACS at 48 h after transfection and replated. Single clones were picked and expanded. Homozygous knockout clones were confirmed by genomic PCR, Sanger sequencing and western blotting.Plasmids

[0169] pCAG-IP-mKO and pCAG-IP-eGFP plasmids were gifts. piggyBac-eGFP-H2B and piggyBac transposase plasmids were gifts. piggyBac-mScarlet-H2B plasmid was generated by cloning mScarlet coding sequence and replaced eGFP coding sequence in piggyBac- eGFP-H2B. pSpCas9(BB)-2A-eGFP (PX458) plasmid was purchased from Addgene (plasmid 48138).Mouse embryo collection and electroporation

[0170] Homozygous Mavs knockout or WT C57BL / 6 female mice (4-11 weeks old) were superovulated by intraperitoneal (IP) injection with 7.5 III of PMSG (Prospec), followed by IP injection with 7.5 IU of hCG (Sigma-Aldrich) 48 h later. After mating with homozygous Mavs knockout or WT C57BL / 6 male mice, respectively, embryos were harvested at E2.5 [thepresence of a virginal plug was defined as embryonic day 0.5 (E0.5)] in KSOM-Hepes by flushing oviducts and uterine horns. Embryos were cultured in the defined modified medium (mKSOMaa) until blastocyst stage. For generating Mavs knockout blastocysts by CRISPR / Cas9 gene editing, mouse zygotes were collected from superovulated WT BDF1 female mice (3-4 weeks old) crossed with WT BDF1 males at E0.5 and electroporated with RNP complex of Mavs targeting sgRNA (100 ng pL1) and Cas9 protein (Takara Bio; 500 ng pL-1) using NEPA21 electroporator. The electroporated zygotes were cultured in mKSOMaa until blastocyst stage. Embryo culture was performed in a humidified atmosphere containing 5% (v / v) CO2and 20% (v / v) O2at 37 °C.Microinjection of human iPS cells to mouse blastocysts

[0171] Microinjection of human iPS cells into mouse blastocysts was performed as previously described with slight modifications. Briefly, the embryos having obvious blastocoel at E3.5 were defined as blastocysts and fully expanded blastocysts were used for human iPS cell injections. Single cell suspensions of hiPS cells were added to a 40 pL droplet of KSOM- Hepes containing the blastocysts to be injected. Individual cells were collected into a 20 pm internal diameter of micropipette. Ten cells were introduced into the blastocoel near the ICM. Groups of 10-12 blastocysts were manipulated simultaneously, and each session was limited to 30 min. After microinjection, the blastocysts were cultured in mKSOMaa for at least 1 h until the ex vivo embryo culture or embryo transfer. For ex vivo embryo culture a standard protocol was followed. In brief, injected chimeric blastocysts were placed in ibiTreat p-plate 8 wells (ibidi GabH, 80826) containing IVC1 medium (Cell guidance systems, M11) and cultured for 3 days in a humidified atmosphere containing 5% (v / v) CO2 and 5% (v / v) O2 at 37 °C. IVC1 medium was replaced with equilibrated IVC2 medium (Cell guidance systems, M12) and cultured for additional 2 days. Embryos were imaged using a fluorescence microscope (Echo Laboratories).Mouse embryo transfer

[0172] As surrogates, ICR female mice (8 weeks old or older) in the proestrus were mated with vasectomized ICR male mice to induce pseudopregnancy. Embryo transfer to the surrogate at E2.5 performed surgically under anesthesia with ketamine / xylazine mixture (ARC LITSW). hiPSC- injected blastocysts were loaded to the pipette with air bubble and transferred to the uterine horn, which were preliminary punctured with a 27G needle connected to a 1.5 mL syringe. 12-28 blastocysts were transferred per surrogate. After the transfer, opioid analgesic (Buprenorphine HCL) was treated. Pregnant female mice were euthanized on E8.5- E9.5, embryos were dissected and used for downstream analysis.Genomic PCR

[0173] Genomic PGR was performed for detecting human-specific DNA in mouse embryos by DNA fingerprinting using primers for TPA25-Alu. Genomic DNA of E8.5-E9.5 mouse embryos and HFF-hiPS cells (used as a positive control) were extracted using DNeasy Blood and Tissue Kit (Qiagen) following the manufacturer's instructions, and then diluted to 30 ng iL’1as PGR templates. Genomic PCRs were performed using Hot Start Taq 2x Master Mix (NEB). PTGER2 primers that bind to conserved sequences in both human and mouse were used as internal control. The PGR products were examined by 2% agarose gel electrophoresis. Primer sequences are provided in Table 1.Fluorescence imaging and immunohistochemistry analysis of mouse embryos

[0174] Imaging of chimeric embryos was performed with a Zeiss Axio Zoom.V16 fluorescence stereo zoom microscope equipped with a Plan-Neofluar Z 1.0x / 0.25 (FWD 56 mm) objective and Axiocam 503 monochromatic camera. GFP-positive embryos were embedded in O.C.T. compound (Fisher Healthcare) without fixation and frozen on dry ice. Sections (12 pm thick) were cut on a cryostat (Leica CM 1950), mounted on the glass slides (Denville Scientific), and stored at -80 °C for immunohistochemistry. All extra-sections and GFP-negative embryos were subjected to DNA extraction and genotyping for Mavs. For immunohistochemistry, sections were fixed in 4% paraformaldehyde (PFA) for 30 min at 4 °C, washed with PBS twice and permeabilized with 0.3% Triton X-100 (Fisher BioReagents) in PBS twice for 5 min at room temperature. After antigen retrieval with 10 mM Citrate (pH 6.0) containing 0.05% Tween 20 (Fisher BioReagents) for 10 min at 90-95 °C, sections were blocked with blocking buffer [5% (w / v) donkey serum (Sigma-Aldrich) and 0.3% (v / v) Triton X- 100 in PBS] for 1 h. Then sections were incubated with the primary antibody (chicken anti- GFP, Table 2) diluted in blocking buffer at 4 °C overnight, donorary antibody (Donkey antichicken IgY conjugated with FITC, Table 2) in blocking buffer at room temperature for 1 h, and finally 5 ng / mL DAPI solution at room temperature for 10 min. Autofluorescence was silenced with TrueBlack Lipofuscin Quencher (Biotium, diluted 1 :20 in 70% ethanol) and slides were mounted with PVA-DABCO. Samples were imaged using a confocal microscope (Zeiss LSM 700).Immunofluorescence

[0175] Cells grown on coverslips were fixed in 4% paraformaldehyde (PFA) for 10 min at room temperature, permeabilized with 0.1% Triton X-100 for 15 min, and blocked with 5% BSA and 0.1% Triton X-100 for 1 h. Incubation with primary antibodies (Table 2) in 1% BSA and 0.1% Triton X-100 was performed overnight at 4 °C. Incubation with donorary antibodies(Table 2) in 1% BSA and 0.1 % Triton X-100 was performed for 1 h at room temperature. DAPI staining was applied for 10 min at room temperature. Coverslips were then mounted with PVA- DABCO on glass slides. The images of stained slides were taken by Revolve (ECHO) or Leica SP8 confocal microscope.Flow cytometry

[0176] Cells were dissociated using TrypLE and fixed in 4% PFA for 10 min at room temperature. Then cells were resuspended with PBS and subjected to flow cytometry analysis. Flow cytometry was performed using FACSCalibur system (BD Bioscience) and analyzed using FlowJo (10.8.1).Western blotting and Native gel electrophoresis

[0177] For western blotting, cells were lysed with RIPA Lysis Buffer (Thermo Fisher Scientific) with protease inhibitor on ice and centrifuged at 12,000 g. The supernatant was mixed with 4* SDS Loading Buffer (Bio-Rad) and boiled at 95°C for 10 min. Samples were loaded into 4-20% Tris-Glycine gel (Invitrogen Novex WedgeWell 4 to 20%, Tris-Glycine) and run at 150 V for 60 min. The gels were then transferred to PVDF membranes (Bio-Rad) and blocked with 5% milk in TBST. Membranes were incubated with the corresponding primary antibodies (Table 2). Immunoreactive bands were visualized using HRP conjugated donorary antibodies (Table 2) incubated with chemiluminescence substrate (Pierce ECL western substrate, Thermo Fisher Scientific) and exposed to X-ray film. For native gel electrophoresis, cells were lysed with Lysis Buffer (20 mM Tris-HCI, pH 7.5, 150 mM NaCI, 10% Glycerol, 1% NP-40, 5 mM NasVO4 and protease inhibitor) on ice followed by 12,000 g centrifugation. The supernatant was mixed with 5* Native Loading Buffer (125 mM Tris, 0.96 M Glycine, 40% Glycerol, 0.005% Bromophenol Blue and 2% DOC-Na). The Cathode Buffer (25 mM Tris, 192 mM Glycine and 0.4% DOC-Na) and the Anode Buffer (25 mM Tris and 192 mM Glycine) were applied. 10% Tris-Glycine gel (Invitrogen Novex 10% Tris-Glycine gel) was pre-run at 200V for 70 min in the cold room until current dropped to 10 mA / Gel. The samples were loaded and run at 200 V for 60 min in the cold room. The gels were then transferred, blocked with 5% milk in TBST and blotted with anti-IRF3 antibody (Table 3).Table 3: List of Primary and Donorary antibodies used in the studyRNA isolation and quantitative RT-PCR analysis

[0178] Both co-cultured and separately cultured cells were sorted out and collected based on fluorescent labelling using FACS at each of the indicated time points. Total RNAs were extracted using RNeasy Mini Kit (Qiagen). cDNA was synthesized using iScript™ Reverse Transcription Supermix (Bio-Rad). Quantitative reverse transcription PCR (qRT-PCR) was carried out using SYBR Green Master Mix (Qiagen) on CFX384 system (Bio-Rad). Reactions were run in triplicate and expression level of each gene was normalized to the geometric mean of Gapdh as a housekeeping gene and analysed by using the AACt method by Bio-Rad Maestro 1.0. The qRT-PCR primer sequences of each gene are listed in Table 1.Bulk RNA-seq quality control and data analysis

[0179] RNA-seq reads were host filtered by SOAPnuke (Version: 1.5.6) with parameters “-I 15 -q 0.2 -n 0.05 -Q 2”. The high-quality reads were mapped to the mouse genome (2020-A, mm 10) and the human genome (2020-A, GRCh38) downloaded from the 10X Genomics website using HISAT2 (Version: 2.1.0) with parameters “-k 1 -p 2 -S -novel-splicesite-outfile -q -no-unal -dta -un-conc-gz”. SAMtools (Version: 1.5) was used to sort the BAM files produced by HISAT2. The expression levels of annotated genes were calculated by transcript per million (TPM) using StringTie (Version: 2.1.4) with parameters “-t -C -e -B -A -p 2”. Fold change was calculated by TPM+1 to avoid infinity. A fold change >= 2 or <= 0.5, a P value and an adjusted R value calculated by DESeq2 less than 0.05 and 0.1 , were used as cutoffsto define differentially expressed genes. KEGG pathway enrichment analyses of up-regulated mouse and human genes were performed by DAVID (Version: 2021 Update) with mouse (Mus musculus) and human (Homo sapiens) as the backgrounds. Default thresholds (Count > 2, EASE < 0.1) were used to define enriched KEGG pathways. scRNA-seq quality control and data analysis

[0180] scRNA-seq reads were processed by Cell Ranger (Version: 5.0.1) using parameters “-localcores=24 --localmem=400 --transcriptome --fastqs” with the mouse genome annotation (2020-A, mm10) and the human genome annotation (2020-A, GRCh38). Multigenome analysis using the human-mouse genome (GRCh38-and-mm10-2020-A) of Cell Ranger was performed to distinguish mouse cells and human cells from cross-species doublets. scRNA- seq analysis was performed using Seurat (Version: 4.0.4). DoubletFinder (Version: 2.0.3) was used to remove intra-species doublets with parameters “pN = 0.25 , nExp =round(0.05*length(colnames(obj)))”. Clusters of mouse embryonic fibroblasts (MEFs) were removed based on the following features: (1) they were present in all samples; (2) they were mouse cells; (3) they expressed marker genes of MEFs; and (4) they did not express marker genes of mEpiSCs. For mouse cells, cells with less than 500 genes or UMI less than 1 ,000 or mitochondrial ratio greater than 10% were removed. Finally, a total of 16,225 mouse cells were kept for further analysis. Cell clustering and Uniform Manifold Approximation and Projection (UMAP) visualization were performed using the “FindClusters” and “RunUMAP” functions of Seurat, respectively.Identification of mouse- / human-specific and eGFP- / h KO-specific reads

[0181] To identify species- or fluorescent gene-specific reads, the high-quality bulk RNA- seq of each sample and scRNA-seq reads of each cell were mapped to both mouse and human genomes, or eGFP and hKO sequences, respectively. Reads that could be mapped to both genomes or both fluorescent gene sequences were removed. This process was repeated many times until there were only species- or fluorescent gene-specific reads left, which were used to calculate mouse / human genome mapping rates, measure eGFP / hKO expression levels, and detect eGFP7hK0+cells. Reads per million (RPM) was used to calculate normalized expression levels of human transcripts and eGFP / hKO. eGFP+ / hKO+cells were defined as cells with eGFP- / hKO-specific reads >=1.Retrotransposable element analysis

[0182] RNA sequencing fastq files were preprocessed with Cutadapt v. 1.18 and Prinseq v. 0.20.4 to remove residual adapter sequences, low quality reads and bases. Remaining reads were aligned with STAR v. 2.6.0 (--twopassMode Basic --outFilterMultimapScoreRange 2 --winAnchorMultimapNmax 1000 --outFilterMultimapNmax 10000 --outFilterMismatchNmax 20 --scoreDelOpen -1 --scoreDelBase -1 --scorelnsOpen -1 --scorelnsBase -1) to both the hg38 assembly of the human genome and the mm 10 assembly of the mouse genome using the IICSC transcriptome annotation. Picard v. 2.18.9 (http: / / broadinstitute.github.io / picard / ) and SAMtools v. 1.9 were used to identify and filter PCR duplicates. Read counting was performed with HTseq v. 0.11.0 using only unique reads aligning to IICSC annotated gene transcripts. The resulting gene counts file was used for Deseq2 v 2.11.40.6 TMM normalization and differential gene expression analysis. Normalized stranded bigwig files for visualization were generated using the Deeptools v 3.0.1 BamCoverage tool (--binSize 5 --normalizellsing CPM --minMappingQuality 255 --filterRNAstrand forward / reverse --samFlagExclude 1024). Retroelement expression levels were determined using a customized pipeline. A general transfer format (GTF) file containing RepeatMasker retroelement annotations was generated for the hg38 human and mm10 mouse genome assemblies. This annotation file contains the genomic coordinates, strand, conservation scores relative to consensus sequence, and relational information for RepeatMasker each annotated repetitive element (element name, repeat family, and repeat class). The highly conserved, full length retroelement copies present in these genomes were further identified and denoted. Reads aligning to individual repetitive elements, reads aligning to specific families of repeat elements, and reads aligning to repetitive sequences classes were counted using HTseq. Reads multiply mapped to more than one individual copy of an element, element within a given family or class of elements were counted only once when calculating read counts at the element, class or family levels. Repetitive sequence read counts were normalized using the Deseq2 scale factors generated above. As a quality control metric, reads derived from the opposite strand from the retroelement-encoding strand were also counted.Statistics

[0183] Data were presented as mean ± s.e.m. from at least three independent experiments. Differences between groups were evaluated by Student’s t-test (two-sided) or one-way ANOVA with Dunnett’s multiple comparison and considered to be statistically significant if P < 0.05. Graphic analyses were done using GraphPad Prism version 9.0 (GraphPad Software). Statistical analyses were done using the Microsoft Excel (Microsoft 365).Example 2: RNA-seq analysis of co-cultured mouse epiblast stem cells.

[0184] Experiments were conducted to determine the genes and pathways that effect and / or favor the dominance of non-human cells in chimeric cell populations. To this end, RNA sequencing (RNA-seq) of separately cultured and co-cultured mEpiSCs was performed. H9 human embryonic stem (ES) cells and mEpiSCs were labeled with enhanced greenfluorescent protein (eGFP) and monomeric Kusabira Orange (mKO), respectively. Mouse EpiSCs from day 1-3 co-cultures were isolated and separated in cultures by fluorescence- activated single cell sorting (FACS) for RNA-seq (FIG. 1A-1D). Comparative transcriptome analysis identified 422, 301 and 77 upregulated genes on days 1 , 2 and 3, respectively, in cocultured versus separately cultured mEpiSCs (co-culture upregulated genes, or co-URGs) (FIG. 1 E). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed using these co-URGs. Interestingly, many overrepresented pathways in days 1 and 2 co-URG groups were related to virus infection and innate immunity (FIG. 1 F-1 H, Tables 4A, 4B and 4C). Among them, retinoic acid-inducible gene I (RIG-l)-like receptor (RLR) signaling pathway represents one of the major RNA sensing systems in mammalian cells, which can be activated by viral and host-derived RNAs. RLR activation results in the transcriptional induction of type I interferons that mounts an antiviral host response. RLR signaling participates in the maintenance of homeostatic genetic stability of cell populations and self-protection. Several key component genes of the RLR pathway were significantly upregulated in days 1-2 cocultured versus separately cultured mEpiSCs, including the cytoplasmic RNA sensors Ddx58 (RIG-I) and Ifihl (MDA5) and the downstream transcription factor Irf718 (FIG. 1I-1 M).Example 3: Characterization of RLR pathway in mEpiSC

[0185] Next, the presence of RLR pathway in mEpiSCs was further characterized. To this end, mEpiSCs were transfected with polyinosinic: polycytidylic acid (also known as poly (I :C)) , a double-stranded RNA analogue that can activate RLRs. Native gel electrophoresis and western blotting revealed IRF3 dimerization, demonstrating an activated RLR signaling in poly (l:C) transfected mEpiSCs (FIG. 2A). To confirm RLR pathway activation in mEpiSCs cocultured with H9 hES cells, FACS-isolated mEpiSCs from day 2 co-culture and separate culture were subjected to protein extraction and native gel electrophoresis. Consistent with RNA-seq results, RLR pathway was found to be activated as evidenced by IRF3 dimerization in co-cultured but not separately cultured mEpiSCs (FIG. 2A). RLR pathway activation in cocultured mEpiSCs seems to be contact-dependent as no upregulation of RLR-pathway-related genes was observed in mEpiSCs co-cultured with H9 hES cells in trans-wells (FIG. 2B). Interestingly, when P65KO-hiPSCs were used for co-culture, upregulated expression of RLR- pathway-related genes were still observed in mEpiSCs (FIG. 2C and 2D), demonstrating RLR signaling activation in mEpiSCs is independent of the outcomes of hPSCs during co-culture. In contrast to mEpiSCs, there was no apparent activation of the RLR signaling pathway in co- cultured H9 hES cells (FIG. 2E-2M, Table 5). Collectively, during co-culture with loser hPSCs, the results uncovered an intriguing cell contact-dependent activation of RLRs in winner mEpiSCs.

[0186] Mitochondrial anti-viral signaling protein (MAVS) is the central hub for RLR sensorsand downstream signaling. To determine whether RLR signaling contributes to human-mouse PSC competition, Mavs gene was knocked out in mEpiSCs (MavsKOmEpiSCs) and confirmed Mavs deficiency did not affect self-renewal, proliferation and expression of key pluripotency transcription factors (FIG. 3A-3C). IRF3 dimerization signal was lost in day 2 co-cultured MavsKOmEpiSCs (FIG. 2A) and most RLR-pathway-related genes were expressed at comparable levels to separate cultures (FIG. 3D), demonstrating Mavs knockout is effective in blocking RLR signaling in co-cultured mEpiSCs. Time-lapse confocal microscopy revealed better survival of H9 hES cells during co-culture with / WavsKOmEpiSCs than with WT mEpiSCs. Next, the cell densities were calculated (cell number per cm2) of live H9 hES cells and mEpiSCs in co-culture and separate culture daily until they grew to confluency (days 1-5). A more rapid elimination of H9 hES cells was observed during co-culture with WT than with MavsK° mEpiSCs (FIG. 3E and 3F). These results suggest compromised competitiveness of MavsKOmEpiSCs. Higher cell plating densities were also tested. Notably, on day 3, significantly more H9 hES cells were found in co-cultures with MavsK° than with WT mEpiSCs (FIG. 3G-3I). To confirm this finding with an independent method, automatic cell recognition and unbiased counting was performed by using an image analysis software. To this end, eGFP-H2B labeled WT or MavsK° mEpiSCs and / or mScarlet-H2B labeled H9 hES cells were plated in micropatterned plates. Fluorescence images were recorded over time for each micropatterned colony using confocal microscopy followed by image analysis and automated cell counting (see Methods). In consistent, on day 3, significantly higher numbers of live H9 hES cells were present in co-cultures with MavsKOthan with WT mEpiSCs (FIG. 3J and 3K).

[0187] Interestingly, during co-culture with H9 hES cells, more MavsKOmEpiSCs appeared to undergo cell death than WT mEpiSCs. In addition, starting from day 4, in contrast to WT mEpiSCs, significantly lower densities of MavsKOmEpiSCs were found in co-cultures than separate cultures (FIG. 3E and 3F). These results suggest reduced viability of MavsKOmEpiSCs during co-culture with H9 hES cells. In addition to Mavs, individual genes upstream (Ddx58, Ifihl) and downstream (Irf7) of Mavs in the RLR pathway in mEpiSCs were knocked out. Ddx58K°-, lfih1K°- and / rf7KO-mEpiSCs all could be passaged long term in culture and maintained the expression of OCT4 and SOX2 (FIG. 4A and 4B). Similar to Mavs, deficiency of Ddx58, Ifihl and Irf7 also led to the significant reduction in mEpiSC densities during cocultures with H9 hES cells (FIG. 4C, FIG. 4D-4G). Together, these results reveal that both cell competitiveness and viability were compromised in winner mEpiSCs by depleting Mavs, and demonstrate the important role of RLR pathway in human-mouse PSC competition.

[0188] In addition to human cells, mEpiSCs could outcompete rhesus macaque and bovine ES cells during co-cultures. Next, the role of RLR signaling in PSC competition between mouse and other species was explored. WT and MavsKOmEpiSCs were co-cultured withrhesus (ORMES23) and bovine ES cells, respectively. On days 4-5, there were evidently more rhesus and bovine ES cells remained in co-cultures with / WavsKOthan with WT mEpiSCs, while significantly less MavsK° mEpiSCs were found in co-cultures than WT mEpiSCs (FIG. 4H-4M). These findings demonstrate that, in the presence of rhesus and bovine ES cells, Mavs deficiency also diminished the competitiveness and fitness of mEpiSCs. When compared with separately cultured mEpiSCs, many RLR-pathway-related genes were upregulated in days 1- 3 mEpiSCs co-cultured with bovine ES cells (FIG. 4N), consistent with what was found in human-mouse PSC co-cultures. Collectively, these results suggest conserved roles of RLR signaling during competitive interactions of mEpiSCs with primed PSCs from other species.Example 4: Suppression of RLR Signaling in host mouse embryos can improve donor hPSC survival

[0189] To determine whether the suppression of RLR signaling in host mouse embryos could improve donor hPSC survival, the same number (10) of eGFP labeled hiPSCs were microinjected into WT and Mavs'1' mouse blastocysts followed by ex vivo culture (FIG. 5A). After 3 and 5 days, eGFP signals were detected in most Mavs'1' embryos injected with hiPSCs, whereas fewer WT embryos contained eGFP+ human cells (FIG. 5B and 5C). To study human cell survival in / Wavs-deficient mouse embryos in vivo, WT mouse embryos were electroporated with Cas9 protein and Mavs targeting sgRNAs at zygote stage, microinjected eGFP+ hiPSCs to the blastocysts and then embryo transfer was performed (FIG. 5A). The percentages of embryonic day (E) 8.5-9.5 mouse embryos containing eGFP+ signals were 18.75% (6 out of 32) for Mavs'1', but only 5.26% (1 out of 19) for Mavs+I' and 0% (0 out of 9) for Mavs+I+(FIG. 5D). The presence of human cells in E8.5-9.5 Mavs'1' embryos was validated by immunostaining of eGFP (FIG. 5E) and genomic PCR using human-specific Alu {TPA25- Alu) primers (FIG. 5F). Together, these results demonstrate genetic inactivation of RLR signaling in the host could improve unmodified donor human cell survival in early mouse embryos.Example 5: Human transcripts in co-cultured mEpiSCs

[0190] Horizontal RNA transfer mediated by exosomes, free extracellular ribonucleoprotein (RNP) particles, or tunneling nanotubes has been observed in mammal. It was speculated that the observed RLR signaling pathway activation in mEpiSCs during co-culture with hPSCs was likely caused by interspecies (human-to-mouse) horizontal RNA transfer. To look for evidence, the RNA-seq (bulk) data, which was generated from FACS-sorted cells based on fluorescence (human, eGFP; mouse, mKO) to minimize cross-species contamination, was revisited (FIG. 1A). To find out whether human RNAs are present in mEpiSCs, mouse- and human-specific reads were host identified, and only these species-specific reads were used to calculate human genome mapping rates for each sequenced sample (FIG. 6A). Interestingly, a smallproportion of human-specific reads were detected in co-cultured mEpiSCs (0.57%, 1.30% and 0.33%, for day 1 , day 2, and day 3, respectively), which were most prominent on day 2 and consistent with the finding on RLR signaling activation (FIG. 6B, 1E, and 11). Similar results were obtained from mEpiSCs co-cultured with P65KO-hiPSCs (FIG. 6C). The same analysis was performed using RNA-seq data generated from non-contact (transwell) co-cultures (FIG. 6D). Interestingly, human-specific reads were barely detectable in both transwell co-cultured (0.05%) or separately cultured mEpiSCs (0.03%) (FIG. 6B) Together, these results reveal the presence of human transcripts in co-cultured mEpiSCs, and suggest putative horizontal RNA transfer through physical connections (e.g., membrane nanotubes (e.g., extracellular vesicles).

[0191] The abundance of human transcripts in co-cultured mEpiSCs was determined and found to be positively correlated with gene expression levels in separately cultured H9 hES cells (FIG. 6E). Stress- induced transcription of retrotransposable elements (REs) has recently been recognized to play an important role in RNA immune response. Therefore, Multi-mapped reads in these RNA-seq datasets were interrogated using pipelines. I ntriguingly , the presence of human RNAs coding for both young and ancient retroelements in mouse EpiSCs, which was contact-dependent and correlated with abundance and peaked at day 2 were detected (FIG. 6F, 6G). Of note is that the expression levels of human retroelements in H9 hES cells were not affected by culture conditions (FIG. 6H-K). Therefore, retroelement RNAs may contribute to RLR signaling activation in mouse cells. In addition, the non-functional exogenous eGFP sequences could also be detected in mEpiSCs specifically under co- cultured condition (FIG. 6L), providing further evidence that the putative interspecies horizontal RNA transfer process is random instead of selectively active transport.

[0192] To rule out the possibility that the co-cultured mEpiSCs collected by FACS was contaminated with small amounts of human cells, single cell RNA-seq was performed (scRNA- seq), using mEpiSCs isolated from day 2 co-culture and separate culture. After filtering out cells with low quality, transcriptome datasets were obtained from 16,225 cells including 6,969 and 9,256 cells in separate and co-cultured conditions, respectively (FIG. 6M and 6N). Unsupervised clustering was performed and 9 clusters were identified (Fig. 4D). Significant differences seen in cell composition between separate and co-cultures: C2, C3 and C6 clusters predominantly consisted of co-cultured cells, whereas C1 and C4 clusters were mainly from cells in separate culture (FIG. 60). To account for possible cell fusion or doublet generated in scRNA-seq library preparation process, as a control, “cross-species doublets” identified by multi-genome analysis by Cell Ranger were included. Consistent with bulk RNA- seq, scRNA-seq data also revealed significantly elevated mapping rates (~1 .2%) to the human genome in co-cultured mEpiSCs, which was significantly higher than in separately culturedmEpiSCs (-0.1%) and much lower than “cross-species doublet” (-40.2%) (FIG. 6P). LIMAP visualization revealed that the presence of human RNAs could be detected in many cocultured mEpiSCs (FIG. 6Q). In addition, eGFP transcripts from human cells were significantly increased in co-cultured versus separately cultured mEpiSCs, which was also significantly lower than those in “cross-species doublet” (FIG. 6R-6T). Next, based on the scRNA-seq data, expression correlation analysis of human transcripts was performed, and high Pearson correlation coefficients (PCCs) was found between co-cultured mEpiSCs and H9 hES cells, especially, genes with higher expression level in H9 hES cells are more likely to be detected in co-cultured mEpiSCs (FIG. 6U). These results confirmed the presence of human RNA in co-cultured mEpiSCs at single cell level and further suggest that the putative human-to-mouse RNA transfer is non-selective.Example 6: Genetic inactivation of Mavs, Ddx58, and Tlr3 in mEpiSCs protect human cell survival during human-mouse PSC co-culture.

[0193] In order to confirm enhanced cell survival of hES in co-cultures with RLR pathway deficient mEpiSCs growth curves of H9 hES cells were plotted when co-cultured with in MavsKO, Ddx58KO, lfih1KO, IrfT^, MavsKOTlr3KO, lrf3KOIrfT*0and Traded0mEpiSCs. As shown in FIG. 7A-7G, in each case with the exception of lifT*0single knockout, the hES exhibited better growth than when co-cultured with WT mEpiSCs.Example 7: Genetic inactivation of Mavs in mouse embryos improves donor human cell survival during chimera formation.

[0194] To further confirm the enhanced cell survival of human stem cells in mice deficient in one or more RLR pathway genes, ex vivo and in vivo experiments were conducted using mice blastocysts either further growth in culture or implanted into mice. eGFP labeled hiPSCs were microinjected into WT and knockout mouse blastocysts followed by ex vivo and in vivo culture. Figure 8A provides a schematic of the experimental set-up for generation of ex vivo and in vivo human-mouse chimera using Mavs-deficient mouse blastocysts. WT and MavsKOmouse embryos cultured for 3 days (d3) and 5 days (d5) after blastocyst injection with hiPSCs were imaged using fluorescence microscopy. Representative images shown in FIG. 8B clearly indicates enhanced growth and maintenance of hiPSCs in the context of the knockout. Line graphs showing the percentages of eGFP+ mouse embryos at indicated time points during ex vivo culture after injecting hiPSCs into WT and MavsK0blastocysts are provided in FIG. 8C. Dot plot showing the percentages of eGFP+ E8.5-10.5 mouse embryos derived from injecting hiPSCs into WT and MavsK° blastocysts as shown in FIG. 8D further confirms enhanced survival of eGFP+cells in MavsK° mouse embryos. Each dot represents one embryo transfer experiment. Blue dots represent experiments using hiPSCs cultured in mTeSR medium whileorange dots represent experiments using hiPSCs cultured in 4CL medium.

[0195] Next genomic PCR analysis of E8.5-10.5 mouse embryos derived from injecting hiPSCs into WT and Mavs1"-0blastocysts was conducted to confirm survival in vivo. TPA25- Alu was used as a human-specific primer and PTGER2 was used as a loading control (see FIG 8E). This experiment was repeated independently three times with similar results showing detectable amplified bands in Mavs1"-0blastocysts. This was also evident from genomic qPCR analysis of E8.5-10.5 mouse embryos derived from injecting hiPSCs into WT and MavsKO blastocysts (FIG. 8F). Human mtDNA was normalized against a conserved element in both human and mouse mtDNA isolated from these embryos (maroon bars), and a 10-fold serial dilution of human:mouse genomic DNAs was used as a standard (grey bars). Red dotted line highlight level equivalent to 1 :104diluted standard.

[0196] E8.5 mouse embryos were sectioned and stained with antibodies against eGFP and lineage markers including PAX6 (ectoderm, top), aSMA (mesoderm, middle) and FOXA2 (endoderm, bottom) (see FIG 8G). The images show enhanced persistence and colonization of eGFP+hiPSCs in the MavsK0blastocysts.Example 6: DISCUSSION

[0197] In summary, the RLR signaling pathway was discovered to be activated in mEpiSCs during interspecies primed PSC competition. Genetic perturbation of key players in the RLR signaling pathway compromised the “winner” status of mEpiSCs, and thereby resulted in better survival of “loser” PSCs from evolutionarily distant species, including humans, rhesus monkeys and cattle. It was further shown that by using Mavs-deficient mouse embryos as hosts, survival of unmodified donor hPSCs could be improved. In addition, the presence of human transcripts encoding unique genes and retro-transposable elements in co-cultured mEpiSCs, putatively as a result a non-selective and contact dependent human-to-mouse RNA transfer was shown. Future studies are warranted to dissect the detailed molecular mechanisms and functional consequences underlying this horizontal RNA transfer between PSCs from different species.

[0198] The study has uncovered an unexpected and intriguing role of RNA innate immunity in interspecies PSC competition and chimerism, and it’ll be interesting to determine whether the same mechanism also operates in “winner” cells in classical cell competition models such as Minute mutant and dMyc. By suppressing the RLR pathway in mouse embryos, the feasibility of modifying the host embryos to boost interspecies chimerism of donor PSCs was demonstrated, providing a framework for generating human tissues in animals that are more suitable for transplant in the future.Table 4ATable 4BTable 4CTable 5

Claims

CLAIMSWhat is claimed is:

1. An engineered pluripotent cell derived from a non-human animal, wherein the engineered pluripotent cell has a functionally defective “retinoic acid-inducible gene I (RIG-l)-like receptor” (RLR) signaling pathway.

2. The engineered pluripotent cell of claim 1, wherein the engineered pluripotent cell is functionally defective for one or more of mitochondrial anti-viral signaling protein Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, lrf7 or any combination thereof.

3. The engineered pluripotent cell of claim 2, wherein the engineered pluripotent cell is a gene knock out or knock in for one or more of Mavs, Rig-1, Mda5, Ikke, Tbk1, Irf3, Irf7 or any combination thereof.

4. The engineered pluripotent cell of claim 2, wherein the engineered pluripotent cell is treated with an inhibitor of one or more of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, Irf7to suppress the retinoic acid-inducible gene I (RIG-l)-like receptor” (RLR) signaling pathway,5. The engineered pluripotent cell of any one of claims 1-4, wherein the engineered pluripotent cell is defective in IRF3 dimerization.

6. The engineered pluripotent cell of claim 1, wherein the engineered pluripotent cell is an epiblast stem cell.

7. The engineered pluripotent cell of claim 1, wherein the non-human animal is a mammal.

8. The engineered pluripotent cell of claim 7, wherein the mammal is a rodent, a porcine, an ovine, or a bovine animal.

9. The engineered pluripotent cell of any one of claim 1-8, further comprising additional genetic modifications.

10. A population of cells comprising at least an engineered pluripotent cell from any one of claims 1-9 or a progeny thereof and at least a human or non-human animal stem cell or a progeny thereof, wherein the human or non-human animal stem cell is any one of an induced pluripotent stem cell, embryonic stem cell, or a variant thereof.

11. A cell culture comprising at least an engineered pluripotent cell from any one of claims 1- 9 or a progeny thereof and at least a human or non-human animal stem cell or a progeny thereof, wherein the human or non-human animal stem cell is any one of an induced pluripotent stem cell, embryonic stem cell, or a variant thereof.

12. A chimeric embryo, tissue or organ comprising an engineered pluripotent cell from any one of claims 1-9 or a progeny thereof and at least a human or non-human animal stem cell or a progeny thereof.

13. A method of producing a human or non-human cell population, a tissue, and / or an organ in a non-human animal of a different species, the method comprising: a) microinjecting a human or non-human animal stem cell in a non-human blastocyst of a different species, thereby generating a chimeric embryo, wherein the non-human blastocyst is functionally defective for one or more of Mavs, Rig-1, Mda5, Ikke, Tbk1, Irf3, Irf7 or any combination thereof.

14. The method of claim 13, wherein the non-human blastocyst comprises a gene knock out or knock in for one or more of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, !rf7 or any combination thereof.

15. The method of claim 13, wherein the blastocyst has been previously administered with a composition comprising a RNA guided nuclease and at least one of a Mavs, Ddx58, !rf7 orlfihl targeting sgRNA at the zygotic stage.

16. The method of claim 15, wherein the sgRNA targets a nucleic acid sequence at least about 90% identical to any one of SEQ ID NOS: 1-7.

17. The method of claim 13, wherein the non-human blastocyst has been treated with an inhibitor of the “retinoic acid-inducible gene I (RIG-l)-like receptor” (RLR) signaling pathway.

18. The method of claim 17, wherein the inhibitor specifically inhibits MAVS, RIG-I, MDA5, or Irf7 protein.

19. The method of claim 13, further comprising growing the blastocyst ex vivo for at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days or more.

20. The method of any one of claims 13-19, further comprising transplanting the chimeric embryo to a surrogate mother.

21. A method for generating a chimeric embryo, the method comprising: a) administering to a zygote of a non-human embryo, a composition comprising an RNA guided nuclease and a sgRNA targeting one or more of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, lrf7 or any combination thereof, thereby causing the cell to be defective in one or more of Mavs, Rig-1, Mda5, Ikks, Tbk1, Irf3, !rf7 or any combination thereof; b) culturing the embryo to a blastocyst stage; c) microinjecting stem cell from a human or a non-human animal from a different species, into the blastocyst to generate a chimeric embryo; d) transferring the chimeric embryo to a surrogate mother, such that the chimeric embryo comprises non-human cell and human cells, or non-human cells from different species.

22. The method of claim 21, wherein the sgRNA targets a nucleic acid sequence at least about 90% identical to any one of SEQ ID NOS: 1-7.

23. The method of claim 21, further comprising growing the chimeric embryo ex vivo for at least 2 days, or at least 3 days, or at least 4 days, or at least 5 days or more before transfer to a surrogate mother.

24. The method of claim 21, wherein the non-human animal is a mammal.

25. The method of claim 24, wherein the mammal is a rodent, a porcine, a bovine, or an ovine.

26. The method of claim 21, wherein the chimeric embryo further comprises additional genetic modifications.

27. Use of a human or non-human chimeric tissue and / or an organ produced by the method of claim 13 or claim 21 , for medical purposes.

28. Use of a human or non-human chimeric tissue and / or an organ produced by the method of claim 13 or claim 21 , for one or more of toxicology, physiology or developmental biological studies.

29. Use of a chimeric organ comprising an engineered pluripotent cell from any one of claims 1-9 or progeny thereof and at least a human or non-human animal stem cell or progeny thereof for transplant in a subject of need thereof.

30. Use of a chimeric organ as in claim 28, wherein the subject is a non-human mammal.

31. Use of a chimeric organ as in claim 28, wherein the subject is a human.

Citation Information

Patent Citations

  • Generation and maintenance of stem cells

    US20190249139A1

  • Compositions and methods for genetic modification and targeting

    WO2022063160A1